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Throughout the last years there has been a considerable number of drugs that 
were discovered thanks to computer aided drug design (CADD) techniques. 
Using the 3D information, such as protein structures obtained by X-ray 
crystallography or nuclear magnetic resonance (NMR), it is possible to identify 
the binding sites and to design molecules that may specifically target these sites. 
This approach saves a lot of time and money, as the lead search is more 
accurate: less compounds need to be synthesised and tested. Although a great 
number of proteins have been successfully targeted with this structure-based 
approach, there are a lot of disease-linked proteins that have been considered 
“undruggable” by conventional structure-based techniques. This is mainly due to 
failure in detection of potential binding sites, which precludes the structure-guided 
design of suitable ligands.  
There is the presumption that the “druggable” human proteome may be larger 
than previously expected. Protein structures may present multiple binding sites 
(allosteric and/or cryptic) that cannot be targeted by the means of conventional 
CADD techniques. In the past years, several novel methods have been 
developed to identify and/or unveil these binding hotspots. Amongst them 
cosolvent Molecular Dynamics (MD) simulations are increasingly popular 
techniques developed for prediction and characterisation of allosteric and cryptic 
binding sites, which can be rendered “druggable” by small molecule ligands. 
Despite their conceptual simplicity and effectiveness, the analysis of cosolvent 
MD trajectories relies on pocket volume data, which requires a high level of 
manual investigation and may introduce a bias. The present study focused on the 
development of the novel cosolvent analysis toolkit (denoted as CAT), as an 
open-source, freely accessible analytical tool, suitable for automated analysis of 
cosolvent MD trajectories. CAT is compatible with popular molecular graphics 
software packages such as UCSF Chimera and VMD. Using a novel hybrid 
empirical force field scoring function, CAT accurately ranked the dynamic 
interactions between the macromolecular target and cosolvent molecular probes.   
iv 
 
Alongside the development of CAT, this work investigated the signal transducer 
activator of transcription 3 (STAT3) as the case study. STAT3 is among the most 
investigated oncogenic transcription factors, as it is highly associated with cancer 
initiation, progression, metastasis, chemoresistance, and immune evasion. 
Constitutive activation of STAT3 by mutations occurs frequently in tumour cells, 
and directly contributes to many malignant phenotypes. The evidence from both 
preclinical and clinical studies have demonstrated that STAT3 plays a critical role 
in several malignancies associated with poor prognosis such as glioblastoma and 
triple-negative breast cancer (TNBC), and STAT3 inhibitors have shown efficacy 
in inhibiting cancer growth and metastasis. Unfortunately, detailed structural 
biology studies on STAT3 as well as target-based drug discovery efforts have 
been hampered by difficulties in the expression and purification of the full length 
STAT3 and a lack of ligand-bound crystal structures. Considering these, 
computational methods offer an attractive strategy for the assessment of 
“druggability” of STAT3 dimers and allow investigations of reported activating and 
inhibiting STAT3 mutants at the atomistic level of detail. This work studied effects 
exerted by reported STAT3 mutations on the protein structure, dynamics, DNA 
binding and dimerisation, thus linking structure, dynamics, energetics, and the 
biological function. By employing a combination of equilibrium molecular 
dynamics (MD) and umbrella sampling (US) simulations to a series of human 
STAT3 dimers, which comprised wild-type protein and four mutations; the work 
presented herein explains the modulation of STAT3 activity by these mutations. 
The binding sites were mapped by the combination of MD simulations, molecular 
docking, and CAT analysis, and the binding mode of a clinical candidate 
napabucasin/BBI-608 at STAT3, which resembles the effect of D570K mutation, 
has been characterised.  
Collectively the results of this study demonstrate the robustness of the newly 
developed CAT methodology and its applicability in computational studies aiming 
at identification of protein “hotspots” in a wide range of protein targets, including 
the challenging ones. This work contributes to understanding the 
activation/inhibition mechanism of STAT3, and it explains the molecular 
mechanism of STAT3 inhibition by BBI-608. Alongside the characterisation of the 
BBI-608 binding mode, a novel binding site amenable to bind small molecule 
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ligands has been discovered in this work, which may pave the way to design 
novel STAT3 inhibitors and to suggest new strategies for pharmacological 
intervention to combat cancers associated with poor prognosis. It is expected that 
the results presented in this dissertation will contribute to an increase of the size 
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Chapter 1 In the search of allosteric binding sites 
1.1 Allostery 
Many protein drug targets exert their activity, when a substrate binds to their 
distinctive active site, promoting their biological function. Classic orthosteric 
ligand may be compared to a competitive inhibitor: a small molecule that 
competes with the endogenous substrate for its occupancy at its cognate binding 
site, thus blocking the protein’s activity (Figure 1). Limitations in applications of 
orthosteric ligands in clinics include a decreased efficacy due to chronic 
administration, limited or poor selectivity, and chemoresistance, occurring when 
crucial binding site residues mutate, changing the landscape of the protein and 
affecting the ligands binding to the protein.1–3 These limitations may be tackled 
by targeting a protein of interest via allosteric regulation. A protein can be 
modulated by small molecules that bind at other regions of the protein (allosteric 
sites), either alone or in the presence of the orthosteric ligand, to stabilise either 
an active or inactive conformation of the system. Regarding the concept of 
allostery, there are two main schools of thought. The first and most classical one 
relies on the MWC model4, which assumes that proteins exist in different 
interconvertible states in the absence of any regulator. The change between the 
different states is regulated by a thermodynamic equilibrium. Furthermore, 
ligands can bind to the receptor in either conformation, which can be altered by 
its affinity with the ligand. Therefore, the binding of a ligand in a state might 
regulate protein activity as it induces a conformational change. A more recent 
and updated view on allostery is the Nussinov model, which insists to put the 
concept of allostery in the framework of cells.5–7 Allosteric effects are propagated 
through their mechanism pathway, and as a consequence, they are likely to 
further affect multiprotein complexes, which are shared by several pathways. 
These observations increase considerably the number of possible combinations 
that an allosteric effect can trigger. The binding of an allosteric ligand unveils a 
unique conformation of the protein that in essence is a new receptor that has a 
propensity for unique pharmacology. Allosteric ligands possess a series of 
advantages that overcome some of the biggest challenges in orthosteric drug 
design. Since allosteric ligands bind at pockets different from the protein , they 
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can afford higher levels of selectivity. This feature is crucial for ligands that 
attempt to target specific receptors that belong to a large family of proteins, such 
as protein kinases or G-protein coupled receptors (GPCR).8 There has been a 
huge effort, albeit with poor results, to produce a series of compounds specific to 
these proteins, mainly due to the highly conserved orthosteric sites, and/or due 
to unfavourable physicochemical and drug metabolism/pharmacokinetic 
properties (ADME) of synthethic orthosteric ligands. Furthermore, it has been 
proven that many direct-acting agonists are toxic or lead to target desensitisation, 
internalisation, or downregulation when they are activated for prolonged periods. 
Allosteric ligands can reach unprecedented levels of selectivity as they target less 
conserved, thus more unique, binding sites at their cognate receptors.1–3,9 
Furthermore, as allosteric ligands bind to a different binding site, there is no need 
to design a candidate that competes with the substrate, meaning that a less 
potent ligand than the orthosteric substrate can show efficacy (Figure 1). 
 
Figure 1 Graphical definition of allostery versus competitive orthosteric inhibition. Small molecule 
inhibitors can be divided in two groups: competitive orthosteric inhibitors and allosteric inhibitors. 
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A competitive inhibitor (red) binds to the proteins binding site competing with the natural substrate 
(green) An allosteric inhibitor (blue) binds to a distinct site on the proteins surface to prevent 
substrate binding (non-competitive inhibition) 
Despite the numerous advantages that allostery can offer over orthosteric 
modulation, it is not a panacea for drug discovery, and there are many 
pharmacological and chemical issues to consider when developing allosteric 
ligands. 
From the pharmacological point of view, allosteric ligands could lead to adverse 
effects, as they might trigger homo- and heterodimer formations for multimeric 
proteins, with unnecessary and/or unknown physiological responses. 
Furthermore, allosteric modulation could induce the formation of different 
oligomeric species, leading to a loss of the orthosteric function of the protein10,11.  
Success stories regarding allosteric sites targeting include Maraviroc, an 
allosteric modulator of CCR5 chemokine receptor that helps tackling the HIV 
infection12. Benzodiazepines have been highly successful therapeutics that 
allosterically regulate ion channels13,14 as well as the AMPA receptors15–17. 
Trametinib is another allosteric inhibitor for kinases MEK1 and MEK2 that was 
approved by the Food and drug administration (FDA) in 2013.18,19 
These are numerous reasons for growing interest in the search of allosteric 
ligands. The discovery of a new allosteric site could bring back to life the interest 
in targets that previously were considered “undrugabble”. Discovery of new 
binding sites means a whole new series of compounds for these targets to be 
discovered.  
1.2 Computer aided drug design 
The main principle of drug design is the assumption that drug activity is exerted 
through the binding to the pocket of a macromolecular target. Chemical and 
geometric/shape complementarity between the ligand and the binding site is 
essential for a successful binding event. The interaction between a ligand and its 
target is usually driven by non-covalent interactions, such as hydrogen-bonds 
and aromatic π-π stacking. The receptors binding site can have a hydrophobic or 
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hydrophilic character, depending on the residues that form them. For example, a 
group of non-polar amino acids like alanine, leucine and/or valine will form a 
hydrophobic pocket.20,21 An example of this feature would be the comparison 
between the recombinant mouse major urinary protein (rMUP) and the 
recombinant histamine binding protein (rRaHBP2), both proteins with similar folds 
but different binding signatures.22 Both systems form part of the lipocalin family 
and present a similar entropy of binding, but while rMUP binds small hydrophobic 
ligands, rRaHBP2 is a “hydrophilic” binder with high affinity for histamine and 
related amines. Nevertheless, binding sites tend to be hydrophobic.However, 
even if a compound binds well to its target, i.e. with high affinity, it does not 
necessarily mean that it is a good drug candidate. The drug must be transported 
from the site of administration (oral, intravenous, etc.) to their target. For 
intracellular targets, this process would involve passing through cell membranes, 
either via pressure (diffusion) or active transport. Once inside the cell, the inhibitor 
must reach its target and later be metabolised and excreted. Therefore, 
properties like solubility or the partition coefficient (logP) are fundamental in the 
small molecule drug development.20,21 Furthermore an additional set of features 
is recommended to be met in order to consider a molecule a drug. Known as 
Lipinski’s rule of five, an orally available drug should have no more than one 
violation to the following criteria: no more than 5 hydrogen bond donors, no more 
than 10 hydrogen bond acceptors, a molecular weight (MW) less than 500 
daltons, and a logP value that does not exceed 5. These criteria should be taken 
more into account as a guide rather than a rule. 
 
Figure 2 Drug discovery pipeline 
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The drug discovery and development is a long and costly process. A drug, in 
order to get approved, must fulfil two main requirements: produce the desired 
response (efficacy) with minimal side-effects (safety), and attempt to be better 
than existing therapies. In the drug discovery pipeline (Figure 2), after target 
identification and validation, the first two steps in many drug discovery programs 
consist in the identification of hits and lead molecules. The hits are compounds 
with some reproducible biological activity of interest. Lead series are usually the 
improvement of the hit. They comprise a set of related molecules that share some 
common structural features and show better or worse activity than the initial hit 
along with an improvement on its drug-like properties such as MW and logP. 
The launch of a new drug to the market costs between 800 and 1600 million GBP 
and it takes between 10 to 15 years to develop.23 In a classical pipeline, 1 out of 
40,000 hits will become a commercial drug. Thanks to CADD techniques, 
nowadays 1 out of 10,000 hits end up in the market.23 
Molecular modelling is a field of research focused on the application of 
fundamental laws of physics and chemistry to the study of molecules and 
biological macromolecules. Molecular modelling techniques have been 
developed as a product of, or in conjunction with, some new technological 
advance such as combinatorial chemistry, high throughput screening (HTS), or 
fast graphical processing units (GPU). In the case of drug discovery, the principal 
aim is to create models and simulations that can predict the properties of 
molecules and their interactions. A correct implementation of these techniques 
means a considerable saving of time and money and an increase of the 
successful rate on the development of a new drug. In some cases there is  
evidence that the use of computer aided drug design (CADD) techniques led to 
an increase of the hit rates in comparison to HTS.24–26 Furthermore, CADD has 
already been used in the discovery of several compounds that have passed 
clinical trials and become novel therapeutics of a variety of diseases. Examples 
include the following: carbonic anhydrase inhibitor dorzolamide, approved in 
199527; the angiotensin-converting enzyme (ACE) inhibitor captopril, approved in 
1981 as an antihypertensive drug28; three therapeutics for the treatment of human 
immunodeficiency virus (HIV): saquinavir (approved in 1995), ritonavir and 
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indinavir (both approved in 1996)25; and tirofiban, a fibrinogen antagonist 
approved in 199829. More recently HIV integrase inhibitor raltegravir30 and human 
renin inhibitor aliskiren31 (both approved in 2007) were discovered through the 
means of CADD. Nevertheless, CADD is still not fully integrated in the drug 
discovery pipeline as most approved drugs did not require crucial involvement of 
CADD. 
CADD techniques can be based in two general types of approach, applied 
independently or in conjunction (Figure 3). Structure based drug design (SBDD) 
analyses the three-dimensional structures of a given target of interest, usually a 
protein, with the objective to identify potential binding sites and/or interactions 
that are key for its respective biological functions. Ligand-based drug design 
(LBDD) relies on known ligands for a target, in order to establish a structure-
activity relationship (SAR) between the physicochemical properties and their 
activity. This information is then used to optimise the already known drugs or 




Figure 3 Basic CADD workflow in drug discovery. Wet-lab methods are coloured blue, SBDD 




1.2.1 Predicting allosteric sites 
Allostery is a very promising phenomenon for drug design, especially in the case 
of proteins for which the design of orthosteric inhibitors has failed. The problem 
relies on the correct identification of the aforementioned allosteric sites. These 
are usually determined by X-ray crystallography: if the target of interest can be 
crystallised in a holo state (ligand-bound), then the binding site can be easily 
characterised. With a known binding site, usually a pocket of a cleft, known, it is 
relatively straightforward to design novel ligands through the means of SBDD 
techniques. For targets with no reported allosteric sites, the situation is more 
challenging. New allosteric ligands cannot be designed if there is no binding site 
mapped.  
To facilitate the mapping of potentially functional allosteric binding sites, a series 
of techniques have been developed in the last years. Some of these techniques 
are outlined below.  
1.2.1.1 Experimental prediction methods 
Allosteric sites have been identified mainly by the means of high throughput 
screening (HTS), which means the screening of thousands or even hundreds of 
thousands of ligands for a given protein target. Techniques based on solution 
Nuclear Magnetic Resonance (NMR) or X-ray crystallography are research-
favorites due to their ability to detect ligand binding, even at low affinity levels (Kd 
values up to 10 mM). In the case of X-ray crystallography, a handful of information 
is provided, since it not only reveals the location of the binding site, but also which 
are the specific protein-ligand interactions. Once a binding site is identified, the 
hit-to-lead process follows to design a series of suitable candidates. Although the 
outcomes of X-ray crystallography are very enlightening for the determination of 
binding sites, there are many limitations related to it. In many cases, due to the 
protein’s behaviour or any other factors such as expression or purification, it is 
close to impossible to crystallise the product of interest. Crystal growth may be a 
slow and tedious process, and even after the protein has been successfully 
crystallised, there is no guarantee that the particular crystal form will be suitable 
for X-ray diffraction.33 Nowadays, the use of novel and promising techniques such 
as cryogenic electron microscopy (CryoEM), and microcrystal electron diffraction 
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(MicroED)34, help to address the need for a fast and reliable structure 
determination. CryoEM changed completely the structure determination game, 
providing an effective and fast tool to determine protein targets that in a previous 
time were near to impossible to crystallise.33,35 The breakthrough of MicroED 
opened the door for the development of a high-throughput MicroED screening, in 
were hundreds of datasets can be collected in a short period of time.36 
Techniques such as Multiple Solvent Crystal Structures (MSCS),37 alanine 
scanning38, and structure activity relationship by nuclear magnetic resonance 
(SAR by NMR)39 have been employed to identify ‘hotspots’ in a number of 
proteins. While MSCS has lost popularity in the last years40, SAR by NMR has 
facilitated the development of several compounds and it continues to be a popular 
technique for fragment based drug design41–46.  
For an identification of a binding site with a higher level of confidence through this 
method, screening compounds would require of a certain size (MM>200 Da) as 
well as complementarity of shape and pharmacophoric interactions47,48. 
Furthermore, the observation of molecule binding to a pocket does not 
necessarily mean that this pocket would have the desirable properties, such as 
size or presence of residues that establish polar interactions with the ligand 
(especially H-bonds), to develop a potential drug based on this site.49 Following 
this idea, Wood and coworkers developed FragLites.50 
This method claims to find potential interacting binding sites through X-ray 
crystallisation with a library of designed small halogenated compounds called 
FragLites. These are defined as small (≤13 heavy atoms) compounds bearing a 
pharmacophore doublet (combination of two functionalities capable of forming 
polar protein-ligand interactions, especially hydrogen bonds) and a heavy 
halogen atom because of their minimal size, maximal simplicity, and high visibility 
in X-ray crystallography due to anomalous scattering of the halogen atom. These 
ligand features give a degree of aqueous solubility that allows them to be used at 
high concentrations in crystallographic and other assay conditions.  
The variation from the small, low affinity ligands to FragLites helps to map our 
targets of interest with more insight. Nevertheless, there is the possibility that a 
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protein might not crystallise. In those cases, the use of computational tools seems 
more feasible for the identification of allosteric hotspots. 
1.2.1.2 Computational prediction methods 
Although the experimental methods mentioned before yield a considerable 
success in the identification of allosteric sites, the toll to pay is high. X-ray 
crystallography can be a “Russian roulette”: determining the optimal conditions 
for protein crystallisation can take a considerable amount of time and resources. 
Furthermore, for protein crystallisation it is required to have the latter expressed 
(bought or expressed in-house) along with the synthesised or purchased 
screening compounds. Approaches involving machine learning6 and Multiple 
Copy Simultaneous Search (MCSS)51, a method that involves a fragment-based 
design approach to identify energetically favourable positions in a pre-specified 
binding site of interest52, among others. Methods involving machine learning rely 
on experimental data, i.e. cryptic pockets solved by X-ray crystallography, whose 
number is very limited53. In MCSS probes do not interact with one another, which 
results in the loss of any possible cooperativity in their binding. Another limitation 
lies in the static structure of the protein target analysed: any ligand-induced 
conformational changes cannot be observed, which precludes its applicability to 
identification of cryptic and transient pockets. MCSS is a very “rigid” method that 
neglects protein flexibility. 
 
Nevertheless, via the means of computational tools one can study the behaviour 
of a protein and even identify new potential binding sites in a shorter time. 
Through last years, thanks to the increasing interest in the matter, a series of 
computational tools and techniques have been developed to identify allosteric 
sites, therefore paving the way for the computational discovery of novel binding 
sites (Table 1).  

































Webservers are the most popular among medicinal chemists. Due to their ease 
of use and fast production of results, researchers use them to identify potential 
binding hotspots. In pocket detection webservers the user inputs a PDB structure 
and waits a short amount of time (minutes to days) to obtain results.  One of the 
most popular pocket detection webservers is the FTMap64. It employs a fast, easy 
to use method based on the sampling of several probe molecules on a densely 
space grid. It uses sixteen different probe molecules which include ethanol, 
isopropanol, isobutanol, acetone, acetaldehyde, dimethyl ether, cyclohexane, 
ethane, acetonitrile, urea, methylamine, phenol, benzaldehyde, benzene, 
acetamide, and N,N-dimethylformamide. This method is very fast because the 
sampling is achieved by an energy function that is evaluated using a fast-Fourier 
transform. FTMap’s energy function incorporates cavity terms to reward 
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hydrophobic enclosure and a statistical, knowledge-based, pair-wise potential to 
account for solvation effects.54 
There are other similar tools that share comparable goals and/or methods 
available such as Cryptosite and Allosite (Table 1). Even if all these methods 
predict allosteric sites based on protein structure, the underlying approach varies 
from the normal mode analysis (NMA) employed in tools such as SPACER and 
AlloPred, to Machine Learning methods in AlloSite and CryptoSite. These tools 
attempt to identify different features, such as structural fluctuations of the protein, 
the effect of different perturbations in the active site or at other specific positions 
or using sequence and structural features. Though webservers achieve a 
remarkable agreement with experimental data54,64, they present some caveats. 
Mainly, the lack of a longer sampling through dynamics affecting the overall cleft 
formation, which restricts its ability to identify new cryptic binding sites. Neglecting 
protein dynamics and flexibility does not allow the user to discover the 
conformational changes of a protein that could lead to the identification of novel 
binding hotspots. 
 
One way to overcome the challenge presented by rigid of crystal structures is to 
employ molecular dynamics (MD) simulations. Briefly, MD consists of calculating 
the trajectory of a system by the application of Newtonian mechanics. Via the 
evolution through the time of the system of interest, its intrinsic dynamics and 
conformational changes can be assessed. This allows for the identification of 




Figure 4 Nowadays proteins can be simulated for hundreds of nanosecond or several 
microseconds but allosteric conformational changes tend to happen around the millisecond 
timescale, where most computers struggle to sample in a considerable amount of time. 
To observe a pocket opening, a conformational change needs to occur: such 
conformational changes often happen in the millisecond time scales (Figure 4). 
The computer power required for simulating these time scales is too demanding. 
Furthermore, biologically relevant events tend to present rough energy 
landscapes, with many local minima separated by high energy barriers. An 
unbiased MD simulation may easily get stuck in a local minimum that is non-
functional or irrelevant for the binding event. Recent studies have demonstrated 
that, in long simulations, proteins can get trapped in irrelevant conformations 
without returning to the original, functionally relevant conformation. It is quite 
common that a protein remains in a local energy minimum for a large fraction of 




Figure 5 Summary of some of the most relevant enhanced sampling techniques67,68  
One strategy to overcome this issue is the use of enhanced sampling techniques. 
These methods add a bias force/potential to the system to overcome the energy 
barrier that grounds the system in a local minimum, providing an acceleration in 
conformational sampling, and therefore allow to study processes such as ligand 
binding or unbinding. Enhanced sampling techniques consist of methods that 
make use of collective variables to introduce the bias, and methods that do not, 
such as replica-exchange MD69. A collective variable (CV) represents degrees of 
freedom of interest or “reaction coordinates” of the system under investigation.  
CV dependent enhanced sampling methods add a bias along the CVs during the 
simulation to observe the process of interest. This process will reduce the energy 
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penalty required to sample and/or observe a conformational change or a 
binding/unbinding event (Figure 5). Some of the most commonly used enhanced 
sampling techniques would be replica exchange MD70, umbrella sampling71 or 
metadynamics72. Especially the last two methods are used for the prediction of 
binding or unbinding events in ligand-protein complexes.  
The main issue regarding the use of enhanced sampling techniques to identify 
allosteric binding sites is that, since these hotspots are unknown, one does not 
know what bias to apply. In most cases there, is no evidence of the 
conformational changes occurring and therefore the use of enhanced sampling 
might not be the best technique to use in the studies of allosteric events. 
Nevertheless, a series of collective variables for the exploration of protein 
druggability have been proposed with promising results. This approach, that 
goues under the name JEDI (Just Exploring the Druggability at Protein Interfaces) 
features a druggability potential that is made of a combination of different 
empirical descriptors73 
 
1.3 Cosolvent MD 
To avoid the bias of enhanced sampling, an alternative approach was proposed 
to overcome the problem of trapping in a local minimum: namely, the cosolvent 
molecular dynamics. In the cosolvent MD, the protein of interest is simulated in a 
mixture of water and small molecule drug-like probes (cosolvents). The 
competition of the probes with water to interact with different protein regions helps 
to map potential allosteric binding sites (Figure 6). Binding of a cosolvent probe 
to the protein may induce conformational changes in the protein in a relatively 
short time scale, thus overcoming one of the aforementioned issues. Also, this 
alternative mapping strategy might be able to unveil cryptic sites that would not 
be discovered by conventional approaches74,75. Due to the novelty of the method 
there is still no evidence in the literature that relates to the discovery of novel 
allosteric or cryptic binding sites with this technique. Nevertheless, different 
cosolvent MD approaches have been benchmarked with successful results74, 




Figure 6 Small molecular fragments could have a different with the protein than water, that can 
lead to the formation of new binding hotspots unvisited in classical MD conditions 
 
1.3.1 Cosolvent methods today 
As with other methods, cosolvent MD can have many flavours, starting from the 
simulation conditions to the scoring energy function that identifies and ranks the 
potential hotspots. As it is a relatively novel method, there is still no consensus 
regarding the best simulation conditions for it (Table 2).  
An important factor to consider while carrying out cosolvent MD is the appropriate 
simulation time. A lot of groups using cosolvent MD choose to perform many 
replicas of short MD (10-30 ns), rather than performing longer (100-1000 ns) 
simulations. Relatively short simulations are chosen to avoid the phase 
separation between water and more hydrophobic cosolvent probes, which would 
lead to unrealistic results. The phase separation problem is related to cosolvent 
concentration: first cosolvent MD attempts were performed at high probe 
concentration (50% v/v) and suffered from a prompt phase separation. Although 
it is important to maximise the number of probes interacting with the protein, 
oversaturation of probe molecules in the system might cause clustering and poor 
sampling. It is recommended to have fewer probes that freely interact with the 
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protein than a higher concentration that may induce artefacts. If, a higher 
concentration is desired, a way to avoid probe clustering and other artefacts is to 
a repulsion potential to the probes, similar to what MacKerell’s group does in 
SILCS for benzene.75 
Another important consideration in cosolvent MD is the probe selection. 
Currently, there is a consensus regarding this aspect. Most cosolvent techniques 
use a series of different probes, individually tested, which share a number of 
features: they should be small drug-like fragments and present a range of 
different functional groups that comprise different degrees of polarity, aromaticity, 
charge and shape diversity. The main idea is to use molecules that achieve the 
same kind of interactions potential drugs could. With the use of small drug-like 
fragments it is easier to extensively map the target of interest, as small molecules 
could interact with different pockets from a potential binding region. By pooling a 
different range of chemical features in the tested cosolvents it would be possible 
to identify which pockets would be more prone for one or another chemical entity 
in the final drug to be designed. The use of Mackerell’s SILCS75 has led to the 
design of novel ligands in proteins such as Mcl-1 or the B-cell lymphoma 6 (BCL6) 
BTB domain (BCL6BTB)76,77. Cosolvent MD does not only help to identify new 
binding sites, but also give a head start on the structure-based ligand design. 
Considering the improvements and evaluations of the existing cosolvent MD 
methods, there is a consensus regarding the simulation conditions. Simulations 
should not be long to avoid unrealistic phase separation. A range of 10-50 ns 
seems to be the optimal one to obtain enough sampling of the tested system. 
Mixture concentration should not exceed 10%, especially in larger systems that 
would require a larger number of probe molecules. It is preferential to perform 
several short MD simulations than a long one. Cosolvent probes must be small-
sized (fragments), drug-like, and range a broad spectrum of polarities. Mixture of 






Table 2 Some of the established cosolvent MD techniques used to identify hotspots and binding 
sites on protein surfaces 
Developer 
(method) 
Cosolvent probes Proteins 
Barril (MDmix)78,79 
Isopropanol, ethanol, acetanitrile, 
methanol, acetamide 
Thermolysin, p53, elastase. 
MDM2, LFA-1/ICAM-1, PTP1B, 




Benzene, propane, water (as a 
hydrogen-bonding probe), 
acetonitrile, methanol, formamide, 
acetaldehyde, methylammonium, 
acetate, imidazole 
BCL-6, trypsin, a-thrombin, 
HIVp, FKBP, Fxa, NadD, Rnase 
A, IL-2, p38 MAPK, DHFR, 
FGFr1 kinase, adenosine 
deaminase, ERα, AmpC, β-
lactamase, T4-L99A, AR, 







HEWL, elastase, p53, Rnase A, 
thermolysin, HIVp, ABL kinase, 
AR, CHK1 kinase, glucokinase, 




Benzene, imidazole, indole, 
pyrimidine, pyridine, 
tetrahydropyran 
TEM-1, IL2, PLK1, NPC2, p38α, 
LfrR, hPNMT 
 
Despite the considerable progress in the development of cosolvent techniques 
achieved in the past years, it is still challenging for the common user to employ 
these methods. Although an experienced computational chemist may conduct 
cosolvent MD with no difficulties, they may need to use some of the scoring and 
analysis methods reported in the literature to evaluate the simulations. Sadly, the 
codes for these analysis tools are usually not available and when they are, one 
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could face several unexpected difficulties upon installation of the code. In some 
cases, the tool is included as a plugin from another molecular visualisation suite 
such as PyMol,81 forcing the user to perform the analysis with this specific 





Chapter 2 Signal transducer and activator of transcription 3 
Signal transducer and activator of transcription 3 (STAT3) protein is a 
transcription factor with the ability to transduce signals from the cell membrane 
to the nucleus to activate gene transcription, thus bypassing the involvement of 
secondary messengers. STAT3 over-expression or inhibition plays an important 
role in processes such as inflammation, cellular proliferation, survival, apoptosis, 
transformation, angiogenesis, invasion and metastasis of cancer85,86.   
2.1 Influence of STAT3 on biological functions 
In its resting state, STAT3 is predominantly localised in the cytosol. STAT3 is 
activated in response to ligand binding to cytokine receptors, including growth 
hormone (GH), prolactin (Prl), and erythropoietin (Epo), as well as several growth 
factor receptors (EGF, insulin, IL-6 and others). When STAT3 is activated, it 
translocates to the nucleus and regulates the expression of certain genes. The 
activation is rapid and transient under normal conditions, but in most cancers 
STAT3 is excessively activated and phosphorylated. Although STAT3 monomers 
tend to be located in the cytoplasm, they can also be found in the mitochondria.87 
Constitutive STAT3 activation results in dysregulation of cell cycle control and 
apoptosis genes. STAT3 has been shown to be constitutively activated or 
overexpressed in breast, lung, prostate, ovarian, colon, gastric and head and 
neck cancers as well as melanoma, leukaemia, multiple myeloma and 
lymphoma88 (Table 3).  
STAT3 activation confers resistance to some conventional therapies that promote 
apoptosis to eliminate tumour cells. In fact, STAT3 drives the expression of 
proliferation and survival genes, like c-my, bcl-XL and mcl-189–91.STAT3’s ability 
to inhibit inflammation has been related to tumour development. The blocking of 
STAT3 signalling in tumour cells leads to the production of inflammatory signals, 
which in turn activates innate immune cells against tumour cells85,86.  
Blocking of STAT3 signalling leads to apoptosis of tumour cells, it also prevents 
the transformation of normal into tumour cells. Therefore, STAT3 is an attractive 
therapeutic target due to its over-expression in tumour cells and the fact that it 
can regulate the expression of a number of genes involved in oncogenesis. 
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Table 3 Status of STAT3 in various cancers 
Cancers Characterized by 
Elevated STAT3 
Expression or Activity 
Poor Prognosis 
Linked to High 
STAT3 Levels 
Upstream/Downstrem 
Abnormalities of STAT3 
Signaling 
Xenograft Models 







Head and neck squamous 
cell carcinoma 




Multiple myeloma Ovarian carcinoma Overexpression of SFKs 
Myeloproliferative 
neoplasms 











- Lung adenocarcinoma 









Cholangiocarcinoma - - - 
Ovarian carcinoma - - - 
Pancreatic 
adenocarcinoma 
- - - 
Melanoma - - - 
Head and neck squamous 
cell carcinoma 




2.2 STAT family 
Seven mammalian STAT family members have been identified: STAT1, STAT2, 
STAT3, STAT4, STAT5 (STAT5A and STAT5B) and STAT6 (Table 4). STAT2, 
STAT4 and STAT6 are only activated in normal human cells. However, STAT1, 
STAT3 and STAT5 play an important role in cancer development. STAT1 acts as 
tumour suppressor, while STAT3 and STAT5 act as oncogenes.85,86 The main 
difference between STAT isoforms is their binding sequence specificity.92 
2.3 Structural features of the STAT family 
STAT proteins have a modular structure that include six different domains: N-
terminal coiled-coil domain, DNA binding domain,linker-domain, SH2 domain, 
and C-terminal transactivation domain (Figure 7).93 Each of these domains are 
important for the physiological functions of STAT proteins.94 The N-terminal 
domain is involved in STAT dimerisation and tetramerisation. While a STAT dimer 
is required to bind to DNA, STATs tetramerisation contributes to stability of that 
binding by interaction with low-affinity STAT binding sites and therefore 
increasing transcriptional activity.95 The DNA-binding domain (residues 320-494 
in human STAT3) forms complexes between STAT and DNA.96 The DNA-binding 
domain binds to DNA as a homodimer, adopting an immunoglobulin-fold 
structure. Between residues 500-585 (493-583 in human STAT3) there is an α-
helix linker domain followed by a SH2-domain97, which spans between residues 
600-700 (583-688 in human STAT3). The SH2-domain is essential for the binding 
of STATs to phosphorylated receptors and for the dimerisation between two 
activated STAT monomers. The dimerisation is enhanced by phospho-
tyrosine/SH2-domain interactions. The C-terminal transactivation domain (723-
770 in human STAT3) is natively unfolded and forms structure only upon binding 
with interacting partners and is involved in communication with transcriptional 
complexes.97 It contains two residues crucial for STAT activation: Y705 and 




















STAT1 N-terminal domain 1-136 Y701 S727 STAT5A N-terminal domain 1-144 Y694 S726 
 Coiled-coil domain 136-315    Coiled-coil domain 145-331   
 DNA-binding 
domain 
316-487    
DNA-binding 
domain 
332-497   
 Linker domain 488-576    Linker domain 498-572   
 SH2 domain 577-682    SH2 domain 592-684   
 Transactivation 
domain 
712-750    
Transactivation 
domain 
706-794   
STAT2 N-terminal domain 1-138 Y690 - STAT5B N-terminal domain 1-144 Y699 S731 
 Coiled-coil domain 139-315    Coiled-coil domain 145-331   
 DNA-binding 
domain 
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Figure 7 Crystal of STAT3-DNA complex (PDB code: 1BG1) displayed in cartoon representation. 
Different domains are colour coded. DNA duplex (blue) is located between the two monomers 
2.4 STAT3 pathway and activation 
STAT3 is involved in the Janus Kinase (JAK) pathway.  It can be activated via 
the tyrosine phosphorylation cascade after ligand binding and stimulation of the 
cytokine receptor-kinase complex and growth factor complex like epidermal 
growth factor receptors (EGFRs), interleukin-6 (IL-6), fibroblast growth factor 
receptors (FGFRs), vascular endothelial growth factor receptors (VEGFRs) and 
more98 (Figure 8). These receptors will induce the phosphorylation of tyrosine 
residues on specific sites at the cytoplasmic domain of the receptors. STAT3 is 
phosphorylated at two sites, Y705 and S727. The phosphorylation of STAT3 
induces its dimerisation via (pTyr)-SH2 domain interactions. Next, the homodimer 
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translocates to the nucleus and activates specific target genes that promote the 
transcription of DNA.  
 
Figure 8 Graphical representation of the STAT3 pathway and small molecule inhibitors proposed 
to act at different stages 
The formation of the dimer is crucial for STAT3 activation. Previously it was 
thought that by suppressing the phosphorylation of STAT3 the pathway would be 
switched off, but recently it has been described that unphosphorylated STAT3 is 
able to form homodimers, via reciprocal interaction of their SH2 domains and 
translocation to the nucleus, where they bind to specific DNA sequences.99 
2.5 Crystal structures of STAT3 
For the structure-guided development of new STAT3 inhibitors, it is required to 
gather information about the protein and more specifically the binding sites. 
Therefore, it is crucial to access the crystal structure for structure-guided studies 
including drug design. Currently, there are only five crystal structures of STAT3 
deposited in the Protein Data Bank:100 
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• 1BG1:101 Phosphorylated STAT3 homodimer bound to DNA (resolution: 
2.25 Å) (organism: Mus musculus) (residues 127-722) (Figure 9A) 
• 3CWG:102 Unphosphorylated STAT3 core fragment (resolution: 3.05 Å) 
(organism :Mus musculus) (residues 127-688) (Figure 9B) 
• 4E68:99 Unphosphorylated STAT3 core fragment bound to DNA 
(resolution: 2.59 Å) (organism: Mus musculus, synthetic construct) 
(residues 127-722) (Figure 9C) 
• 4ZIA:103 Crystal structure of STAT3 N-terminal domain (resolution: 2.70 Å) 
(organism: Mus musculus) (residues 1-127) (Figure 9D) 
• 6QHD:104 Lysine acetylated and tyrosine phosphorylated STAT3 in 
complex with DNA (resolution 2.85 Å) (organism: Homo sapiens) (residues 
127-722) (Figure 9E) 
 
Figure 9 Crystallographic STAT3 structures available to date. A) 1BG1, B) 3CWG, C) 4E68, D) 
4ZIA and E) 6QHD100 
All these structures have some regions of tertiary structure missing in the protein-
protein interaction domains. A flexible loop of residues containing the tyrosine 
residue Y705, which is enhancing dimer stabilisation and interaction surface, is 
missing. This loop interacts with the partner SH2 domain, stabilises the 
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association, and binds their phosphorylated Tyr into a specific binding site on the 
partner SH2 domain. This uncertainty of the structural arrangement makes the 
application of computational drug design techniques very challenging. The lack 
of crystal structures with a bound ligand makes the prediction of potential binding 
sites even more challenging. 
2.6 STAT3 “druggability” studies and reported inhibitors 
STAT3 can be inhibited directly or indirectly. Indirect inhibition of STAT3 can be 
achieved by the blockage of upstream tyrosine kinases or other factors involved 
in the STAT3 pathway. Indirect inhibitors are characterised by a non-selective 
mechanism of actions, which increases the likelihood of undesirable toxicity and 
other adverse off-target effects. 
The problem with this strategy is that the STAT3 pathway may not be effectively 
blocked by a single compound and that compounds may inhibit other downstream 
targets. Furthermore, in cells in which proliferation results from the inactivation of 
negative regulators of signaling the inhibition of upstream signaling pathways 
may have little effect86,105. The nonspecific mechanism of action of indirect 
inhibitors highlights the restriction of this approach. 
Direct inhibition can be achieved by targeting one of the three structural STAT3 
domains: SH2 domain, DNA binding domain, and N-terminal domain. Direct 
inhibition should block one or more processes related to STAT3 signaling, 
including STAT3 phosphorylation, dimerisation, DNA binding, and STAT3-
induced expression of genes. 
Many authors focused on inhibiting the SH2 domain, considering its key role in 
STAT3 activation105–108. The SH2 domain is responsible for the interaction with 
phosphorylated Tyrosine residues within the cytoplasmic portion of the upstream 
receptors. It is also involved in the dimerisation of STAT3. Therefore, inhibition of 
SH2 domain by small molecules is expected to suppress the phosphorylation and 
activation of STAT3, as well as inhibit STAT3-DNA interaction.109 
Several compounds have been reported as binders that effectively compete with 
phosphorylated STAT3 monomers for the pTyr-binding site. Some examples of 
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these inhibitors are the salicylic acid derivatives105, S31-201110, stattic111 and 
S31-1757112 (Figure 8). They all have been described as SH2 inhibitors, but there 
is no conclusive evidence that their mechanism of action is by binding in the pTyr-
binding site. 
Several authors showed discrepancies regarding the SH2 sub-pockets that are 
targeted by small molecule inhibitors. There is no consensus: some authors 
describe three sub-pockets, which do not match in most cases, and some others 
describe only two sub-pockets (Figure 10). There is mostly discrepancy in which 
is the third sub-pocket. 
 
Figure 10 Most reports agree that STAT3 SH2 binding site is formed by three pockets: pY+0, pY-





Table 5 STAT3 binding sites defined by different authors 















K591 M586 S636 K591 S636 K591 M586 
R609 G587 Q635 R609 W623 R609 G587 
S611 F588 T620 S611 Q635 S611 F588 
E612 I589 K626 E612 V637 E612 I589 
S613 S590  S613 Y657 S613 S590 
Shahani et al.105 Siddiquee et al.106 Fletcher et al.110 
Pocket A Pocket B Pocket C Pocket A Pocket B Pocket A Pocket B 
K591 I634 W623 K591 K592 K591 K592 
R609 R595 V637 R609 R595 R609 R595 
S611 E594 I659 S611 I597 S611 R595 
S613 I597 F716 S613 I634 S613 I597 
  K626    I634 
Pallandre et al.116 Zhang et al.105 
Pocket A Pocket B Pocket C Pocket A Pocket B Pocket C 
K591 R595 Q635 T620 K591 R595 I659 
R609 I634 S636 F621 E594 I634 W623 
S611  W623 P639 R609  V637 
S613  V637 Y640 E612  E638 
S614  E638 Y657    
   I659    
 
Table 5 summarises some of the different descriptions by several authors. As 
showed, in most cases the pockets A or pTyr (Figure 10) are identical or highly 
similar, containing K591 and R609 in all descriptions. Residues like R595, W623 
and S636, are present in most identifications, but in some studies completely 
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different pockets are annotated115,117. The lack of a STAT3 co-crystallised with 
ligands hampers the identification of STAT3 binding sites. 
Another issue in the STAT3 binding site annotation is that these binding sites 
have been identified solely by means of molecular docking. Considering the 
number of drug design tools available to date that would be able to validate these 
findings, relying solely on molecular docking results renders those predictions not 
trustworthy and would require further validation studies. 
2.6.1 Classification of direct inhibitors 
The direct inhibitors can be divided into different categories: 
• Peptides were the first compounds designed for inhibiting STAT3 in a 
direct approach. They block aberrant activity of STAT3 in cancer cells via 
preventing protein dimerisation. Their specific target is the SH2 domain, at 
the pY705 level. Starting from the sequence around pTyr705, the first 
phosphopeptide inhibitor PpYLKTK was developed.118 This 
phosphopeptide inhibits STAT3 activity in tumour cell lines, induces cell 
death and has a high affinity and specificity for STAT3.118 
While peptide‐based inhibitors can bind to STAT3 with high affinities, they 
suffer from low metabolic stability and the lack of cellular permeability due 
to their molecular nature and the negative charges on the phosphotyrosine 
group. However, they provided an excellent starting point for the 
development of more cell‐permeable peptidomimetics105,109,119. 
• Peptidomimetics are inhibitors that mimic pYX1X2Q motif and inhibits 
STAT3 dimerisation by competitive binding to the SH2 domain.  
• Natural compounds. Only a small number of natural compounds were 
found to directly target STAT3 protein like cryptotanshinone, a natural 
compound extracted from the root of Salvia Miltiorrhiza Bunge.120,121 
Previously curcumin was thought to be a relevant STAT3 inhibitor but 
recent studies have classified this molecule both as a PAINS (panassay 
interference compounds) and an IMPS (invalid metabolic panaceas), 
proving that curcumin is an unstable, reactive, nonbioavailable compound 
and, therefore, a highly improbable lead.122 
30 
 
• Small molecules. Non‐peptide small‐molecule inhibitors are cell‐
permeable, but most of the reported compounds bind STAT3 with weak 
affinities (IC50 values in the micromolar range) and the cellular activity 
cannot be clearly attributed to STAT3 targeting105,119,123. 
The non‐peptide small molecules represent a more attractive approach for 
inhibiting STAT3 directly, compared to peptides and peptidomimetics, 
given their cell permeability and physicochemical properties. However, 
optimisation of their structures and increasing the binding affinity is 
required to improve their in vivo activity and efficacy. 
• Oligonucleotides represent a new, highly selective and low toxic class of 
drugs for targeting STAT3, which has shown promising results in vivo on 
nude mice xenografts119. 
2.6.2 SH2 domain inhibitors 
Table 6 shows the most relevant STAT3 SH2 domain inhibitors reported up to 
date in the literature. Structures of these compounds are shown in Figure 11. 
Table 6 SH2 domain inhibitors described to date. 

















BBI-608/Napabucasin   
 
Peptidomimetic inhibitors 
• S31‐M2001 (Figure 11) is a novel oxazole‐based peptidomimetic that 
selectively disrupts STAT3 dimerisation and therefore inhibits STAT3 
transcription and migration in both human and mouse cells.118 
Natural compounds.  
• Cryptotanshinone (Figure 11) is a natural compound that binds to the 
SH2 domain and inhibits the formation of STAT3 dimers. 
Cryptotanshinone inhibits the STAT3 phosphorylation and decreases the 
expression of STAT3 downstream target genes involved in cell survival.113 
Small molecules. Some small compounds have been developed to inhibit 
STAT3’s SH2 domain by the means of computational drug design techniques 
such as virtual screening and QSAR.98,101 These include STA‐21, stattic and S31‐
201. 
• S31‐201 (Figure 11) is a low‐molecular‐weight salicylic acid derivate that 
blocks STAT3 dimerisation through SH2 domain binding. Furthermore, 
S31‐201 induces apoptosis in malignant cell by suppressing STAT3‐
dependent expression of cyclin D1, Bcl‐XL, and surviving.103 
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• Stattic (Figure 11) inhibits selectively the dimerisation and DNA binding of 
STAT3, by preventing activating enzymes to the STAT3 SH2 domain. As 
a result, stattic induces apoptosis in breast cancer cell lines.104 
• STA‐21 (Figure 11) is an antibiotic that specifically binds to SH2 domain 
inhibiting the STAT3 dimerisation and nuclear translocations. It has been 
reported that STA‐21 inhibits breast cancer cell growth and survival.100 
• Celecoxib (Figure 11) also binds to the SH2 domain of STAT3 and inhibit 
the binding of the native peptide. It has been reported that this inhibitor 
reduces cell viability and migration in human rhabdomyosarcoma cells.121 
• LLL12 (Figure 11) inhibits STAT3 phosphorylation, DNA-binding and 
induces apoptosis in various cell lines.123 
• TPCA-1 (Figure 11) blocks STAT recruitment to upstream kinases by 
docking into SH2 domain. Is an effective inhibitor of STAT3 




Figure 11 Chemical structures of described STAT3 inhibitors 
2.6.3 Targeting the DNA binding domain BBI-608  
Obtaining a ligand that effectively targets the SH2 domain is a hard quest. Most 
of the described inhibitors did not succeed in the drug design development 
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pipeline due to their poor activity, selectivity and toxicity issues. The lack of a co-
crystallised STAT3 structure impedes a structure-guided drug design, as the most 
favourable protein conformation for binding is unknown. Although many reported 
STAT3 inhibitors are considered to target SH2, none of them has made it to clinic. 
The proposed mode of action (MoA) of those inhibitors remains elusive as it is 
not supported by structural biology data and relies solely on molecular docking 
calculations.  
At the time of writing of this dissertation, only three direct STAT3 inhibitors are 
undergoing clinical trials. OPB-51602 and OPB-31121 (Otsuka Pharmaceuticals) 
have reached early phase clinical trials in both advanced solid 
malignancies127,128. Although signals of efficacy were observed in EGFR inhibitor-
resistant non-small cell lung cancer (NSCLC) and gastrointestinal malignancies, 
the further development of these compounds was limited by concerns over their 
unpredictable PK profiles and potentially severe toxicities129. A plausible 
explanation for these side-effects is the ubiquitous expression of STAT3 within 
the body and its diverse physiological roles, including the modulation of 
mitochondrial metabolism and the immune system130. Second-generation OPB 
compounds with more favourable toxicity profiles have been identified and are 
currently being evaluated in early phase clinical trials128. OPB ligands are claimed 
to bind in the SH2 binding site, but in an allosteric position close to the canonical 
pTyr site. TTI-101 (Tivardi Therapeutics), which is another STAT3 inhibitor, is 
currently being evaluated in Phase I clinical trials for a range of advanced 
cancers, including breast cancer128.TTI-101 is an antisense oligonucleotide and 
its mechanism is completely different from small molecule inhibitors. 
Napabucasin/BBI-608 is a first-in-class cancer stemness inhibitor that 
targets STAT3131 , which is being tested (Phase 3) as a treatment in advanced 
colorectal cancer132. The BBI-608 patent documents contain a solved crystal 
structure of drug-STAT3 complex, with the BBI-608 bound in a pocket between 
the linker and DNA binding domain (Figure 12). The structure has not been 
deposited to the PDB Data Bank, though 133. The community has not been eager 
on targeting the DBD due to the belief that targeting DBD of transcription factors 
has potentially limited selectivity134–136. Hence, DBDs has been considered 
“undrugabble”. This consensus has been challenged by the solution of BBI-608 
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structure bound to the DBD, which serves as “proof-of-concept” for direct 
inhibition of STAT3 DBD by small molecules. BBI-608 has been originally 
described as a SH2 domain inhibitor, and its derivatives are considered as such 
in the literature (again based on insufficient in silico methods such as virtual 
screening). In the recent years, interest in targeting STAT3 DBD has grown, and 
there is already a handful of described inhibitors claim to bind in the DBD based 
on their studies.134,135,137 Small molecule ligands shikonin and the inS family of 
compounds (Figure 11) have been reported as effective STAT3 DBD inhibitors 
as the protein is dimerised upon inhibition135.   
 
Figure 12 BBBI-608 binding conformation as per Ji et al133 
2.7 Inter-domain mutations affect STAT3 activity 
It has been recently reported by Mertens et al.138 that mutations in the linker 
domain strongly suggest contacts between this domain and both the DNA binding 
and SH2 domains. These are likely to cause changes that strongly affect STAT3 
activity. Residues within the linker domain (Figure 13), which form inter-domain 
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interactions, are involved in the hydrogen bonding and are presumably crucial for 
maintaining STAT3 biological activity. W564 forms the H-bond with SH2 domain 
S611, and W546 and K551 form an H-bond with E434. Alanine scanning of these 
residues showed a significantly drop in STAT3 DNA-binding and phosphorylation 
compared to the wild type protein. These destabilising effects could provide a 
plausible mechanism for STAT3 disruption138. 
 
Figure 13 Location of mutated residues in the STAT3 linker domain structure. View of mouse 
STAT3 in complex with DNA (PDB ID: 1BG1). DNA binding domain (red), linker domain (orange) 
and SH2 domain (cyan), are highlighted. Hydrogen bonds are highlighted by yellow dashes and 
distances labelled in angstroms.  
There also several reports that STAT3 undergoes allosteric communication 
across domains.139 Solution NMR analysis shows that during pTyr binding and 
dimer formation (which occurs via the SH2 domain) considerable chemical shift 
perturbations are observed in the linker domain residues which are not directly 
involved in this processes.139 One of the residues with the largest chemical shift 
perturbation upon binding of p-Tyr is I568, an interfacial residue between SH2 
and linker domain, which alongside V572  is involved in hydrophobic interactions 
with F610 in SH2. These results show importance of allosteric sites within STAT3, 
and suggest focusing beyond the SH2 domain as a viable strategy for structure-
guided development of novel STAT3 inhibitors. Potential novel allosteric sites at 
STAT3, which could be mapped, could then be rendered as alternative binding 




Chapter 3 Objectives 
The main goal of this work was to develop a robust computational method to 
identify new, transient and/or cryptic “druggable” sites on hard-to-target proteins, 
such as STAT3. To achieve this goal, the following objectives were proposed: 
1. Develop a workflow to identify potentially “druggable” allosteric and/or 
cryptic binding sites through the means of cosolvent molecular 
dynamics simulations. 
2. Develop a robust, easy-to-use, and open source platform to analyse 
and interpret the results of cosolvent MD simulations, in terms of 
scoring and ranking of the identified “druggable” binding sites. 
3. Apply the developed method in objective 2 to identify potential STAT3 
allosteric binding sites, which could not be identified via conventional 
computational approaches. 
4. Characterise STAT3 SH2 domain “druggability” in terms of the 
behaviour of the activation peptide binding site by means of equilibrium 
atomistic MD simulations and molecular docking studies, in order to 
assess the local flexibility and transient cavities. Molecular docking 
would be performed to evaluate the conservation of the pTyr binding 
site and to identify any potential binding pockets unreported to date. 
5. Assess the effect of reported inter-domain mutations on STAT3 
structure, dynamics, and ligand binding by means of umbrella sampling 
simulations of the STAT3-DNA complexes. These results would enable 
understanding of STAT3 allostery at the atomistic level. 
6. Evaluate the binding mode and the mechanism of action of the STAT3 
inhibitor BBI-608 by means of molecular docking, equilibrium MD, and 
umbrella sampling simulations. The calculated structure of BBI-608 
bound to STAT3 would facilitate the structure-guided design of potent 




Chapter 4 Methodology 
The lack of a detailed understanding of how difficult to target proteins such as 
STAT3 interact with their ligands remains a major roadblock in advancing drug 
discovery efforts and uncover allosteric regulatory mechanisms. Reliable 
mapping of novel binding sites is essential for designing specific inhibitors, thus 
to develop new therapeutics in structure-guided manner. 
This chapter covers the methods applied in this project. A need to include protein 
flexibility throughout binding events and druggability assessment, combined with 
the proteins’ large size, requires usage of methods based on classical molecular 
mechanics, which are relatively fast and proven successful in structure-based 
drug discovery efforts. These comprise molecular dynamics simulations 
(equilibrium as well as enhanced sampling techniques, including cosolvent 
dynamics) and molecular docking/virtual screening. 
4.1 Classical molecular mechanics 
Computational methods applied in structure-based studies of biomolecular 
systems can be divided into two main groups based on their levels of theory. 
Quantum mechanics (QM) describes electrons explicitly, and is used to describe 
the process that involves their movement in atoms (and molecules), like breaking 
or formation of covalent bonds.140 QM methods are very accurate yet they 
requires a high amount of computational resources and time, therefore 
application of these methods is limited to small systems. In classical molecular 
mechanics (MM), which utilises Born-Oppenheimer approximation (Equation 1), 
the electrons are treated implicitly and each atom is treated as a single particle. 
The Born-Oppenheimer approximation dictates that the nucleus motions not 
affected by the electronic movement, given the fact that the nucleus is thousand 
times heavier than the electron. Therefore, the electron-nucleus motion is 
decorrelated and the solution of the problem in the Schrödinger equation can be 
narrowed down to electronic motion only. This allows to study the structure and 
dynamics of large systems such as protein-ligand complexes, but it does not 
permit any covalent bond breaking or making. 
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?̂?Ψ(𝑞𝑖, 𝑄𝐼) = 𝐸Ψ(𝑞𝑖, 𝑄𝐼)     Equation 1 
                  ?̂? =  ?̂? 𝑒𝑙 + ?̂? 𝑁 
Ψ(𝑞𝑖, 𝑄𝐼) ≈ Ψ
𝑒𝑙(𝑞𝑖: 𝑄𝐼)Ψ
𝑁𝑈𝐶(𝑄𝐼) 
 Both MM and QM levels of theory permits to:140 
• Calculate the free binding energy changes associated with the formation 
of non-covalent protein-ligand complexes and determine their properties 
(QM and MM levels of theory) 
• Model the chemical reactions (QM only) 
• Perform conformational analysis of small molecules (QM and MM) 
• Identify the near-native structure of the protein-ligand complex (molecular 
docking) and rank the set of small molecule ligands based on their 
calculated binding affinity to a given protein target (QM and MM; virtual 
screening and hit identification) 
• Suggest the changes in the ligand molecule to improve the binding affinity 
(QM and MM; hit-to-lead and lead optimisation) 
• Assess the flexibility and conformational changes within the system of 
interest (MM; classical molecular dynamics) 
MM relies on three basic principles. The first one, also known as the Anfinsen 
dogma of protein folding, is the thermodynamic hypothesis. It states that a 
(macro)molecule driven by thermodynamic forces will change its conformation 
from the structure that represents a high energy state to a native structure which 
represents the global energy minimum state in a reversible fashion.140,141 The 
second principle, the additive assumption, states that the total potential energy 
(V) of a system can be written as a sum of different potentials with simple physical 
interpretations (bond stretching, angle bending, Coulombic interactions, 
dispersion forces, etc.). The third principle, which is the transferability, is based 
on the assumption that parameters derived from small molecules such as bond 
lengths and angles can be transferred to larger, more complex, macromolecular 
systems, such as proteins and nucleic acids. Therefore, systems of different sizes 
can be studied using the same physical model (the force field). 
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4.1.1 Force field 
The force field is a core concept in classical molecular mechanics, which 
approximates the potential energy of a system with a combination of bonded 
(intramolecular) and non-bonded (intra- and intermolecular) contributions 
(Equation 2).  
𝑉𝑡𝑜𝑡𝑎𝑙 =  𝑉𝑏𝑜𝑛𝑑 + 𝑉𝑎𝑛𝑔𝑙𝑒𝑙 + 𝑉𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 + 𝑉𝐶𝑜𝑢𝑙𝑜𝑚𝑏 + 𝑉𝐿𝐽    Equation 2 
The harmonic terms describing the distortions from equilibrium positions in bond-
stretching and angle-bending can be calculated using Equation 3 and Equation 4 
respectively.140 


















The term constructed to describe the torsional motion of dihedral angles can be 
calculated from (Equation 5). 







(1 + cos (𝑛𝑖ϕ𝑖 − 𝛿)
2) 
Equation 5 
All the above interactions are represented by harmonic potentials for the bond 
lengths  𝑟𝑖, bond angle Θ𝑖, dihedral angle ϕ𝑖  and phase angle 𝛿 that takes values 
of either 0º or 180º.  The kb, k, kϕ  denote the force constants for the bond-
stretching, angle-bending and dihedral angle terms.  
The non-bonded interactions are more distant and not connected by covalent 
bonds. These can be divided in to short-range and long-range. The short-range 
interactions correspond to the van der Waals interactions and describe the 
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repulsion of two atoms due to overlapping valence electrons and attraction due 
to induction and dispersion forces. These interactions are commonly 
approximated by the 12-6 Lennard-Jones potential (Equation  6).142 The distance 
dependence of the repulsion term is proportional to 𝑟𝑖𝑗
−12 inter-atomic distance 
mimicking the exponential soft-wall behaviour, and proportional to 𝑟𝑖𝑗
−6  with 
regards to the attraction. The 12-6 Lennard-Jones potential on a given particle 𝑖 
due to particles j in a system is described by:  
𝑉𝐿𝐽
𝑖𝑗














where 𝜖𝑖𝑗 denotes the depth of the potential well, or region surrounding a local 
minimum of potential energy, and 𝑟𝑖𝑗 is a finite distance at which the inter-particle 
potential is zero. 
The long-range interactions are the consequence of electric charges in the 
system. The individual atoms of a molecule are charged, allowing for the use of 
Coulomb’s law to describe the mutual interactions between two (partial) atomic 
charges, and providing multipoles for molecules or individual charge groups. The 









where 𝜖𝑟𝑒𝑙 is dielectric constant of the medium. The electrostatic interactions 
decrease as 𝑟𝑖𝑗
−1 increases, making them longer ranged than the van der Waals 
interactions. 
The most widely used biomolecular force fields include the AMBER143,144, 
CHARMM145, GROMOS146 and OPLS147 force fields. In this work, AMBER force 
field (AMBERFF99 SB-ILDN148) has been used. These force fields share similar 
mathematical functional forms and they differ in the parameters that describe the 
various energetic components and in the methods used to obtain these 
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parameters. Recent force fields were in the most part defined by fitting 
parameters to data obtained from quantum-level calculations or experiments on 
small molecules thought to mimic the properties of proteins.149 Most of these force 
fields have not changed in some time, but a few parameters such as a few torsion 
angles have been refined to improve their accuracy for proteins and peptides. 
Although, standard and commonly used force fields like Amber ff99-SBILDN tend 
to sample globular proteins reasonably well, their performance is subpar with 
intrinsically disordered proteins (IDPs) and other very flexible regions of a 
protein.150 Therefore, there have been force fields specifically designed to 
properly model the folding of IDPs such as Amber ff03ws, the counterpart was 
that these force fields are so fitted to IDPs that tend to sample the behavior of 
folded proteins. Recently, a rewrite of a99SB by Robutstelli et al (a99SB-disp) 
also helped improve the modelling of IDPs along with an accurate description of 
folded protein properties.151 In this work the Amber ff99-SBILDN was solely used 
for MD simulation as the studied systems correspond to folded proteins. A99SB-
disp could have been used to better sample very flexible regions of the studied 
proteins such as STAT3’s transactivation domain but sadly these corrections 
were not available upon the time the simulations were performed. 
4.2 Molecular dynamics 
Molecular dynamics (MD) consist in a computer simulation technique that 
predicts the time evolution of a system of interacting particles (atoms, molecules, 
beads, etc). An outcome of an MD simulation is a trajectory that specifies how 
the positions and velocities of the particles in the system vary with time. Analysis 
of the trajectory for a given biomolecular system can provide valuable information 
concerning molecular geometries and energies; mean atomic fluctuations; local 
fluctuations (like formation/breakage of hydrogen bonds, water/solute/ion 
interaction patterns, or nucleic-acid backbone torsion or motions); 
enzyme/substrate binding; free energies and even large-scale conformational 
changes of macromolecules such as small protein folding.140 
The principle behind the classical MD is Newton’s second law of motion, used to 
calculate the dynamics of the system (Equation 8). 
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?⃗? = 𝑚?⃗? Equation 8 
If the mass of each particle in the system is known and the forces are derived 
from the interactions with surrounding particles using the force field (Chapter 4.1), 
the acceleration of each particle can be calculated. Then, the instantaneous 
velocity and the displacement can be calculated by the numerical integration from 













The force acting on each atom 𝑖 in the system is given by the negative gradient 
of potential energy function V, which depends on the coordinates of all other 
atoms in the system (Equation 11)140 
?⃗?𝑖(𝑡) =




If the potential energy of the system is known and the coordinates for a starting 
structure and a set of velocities are given, then the force acting on each atom can 
be calculated and a new set of coordinates is generated by advancing the 
simulation in a short span of time called timestep (𝛿𝑡), from which new forces are 
calculated. These integration cycles are usually calculated via a leapfrog 
integration method. This method defines the positions and velocities as time-
dependent Taylor series, which can be integrated to obtain its related primitive 
function. Repetition of this procedure will generate a trajectory corresponding to 
the evolution of the system in time (Figure 14).140 In case the velocities are 
unknown (e.g. first equilibration step) these are calculated from a Maxwell 




Figure 14 An overall scheme of the molecular dynamics simulation 
In order to reproduce the behaviour of real molecules in motion, the force field 
terms are parameterised to fit quantum‐mechanical calculations and 
experimental data. Parameterisation includes identifying the ideal stiffness and 
lengths of the springs that describe chemical bonding and atomic angles, 
determining the most appropriate partial atomic charges used for calculating 
electrostatic‐interaction energies, identifying the proper Van der Waals atomic 
radii, and more.152  
Application of molecular dynamics simulations to ligand-protein interaction are 
still limited by two major roadblocks: inaccuracies in the force fields applied, and  
an insufficient sampling problem, which is related to time scales accessible (up 
to microseconds, due to high computational costs of longer simulations).152 
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4.2.1 Classic/canonical MD 
MD simulations with the atomistic resolution are well-established and deliver a 
generous amount of details and insights for the studied system allowing 
investigation of intra and inter-molecular processes. In the atomistic description, 
each atom in the system is defined as a single interaction centre, and the forces 
acting on it are evaluated every time step. The time step is limited by the fastest 
vibrations in the system (C-H) that corresponds to 1-2 fs. A time step of this size 
allows for stable numerical integration, however, limits the accessible time and a 
total length for biomolecular simulations. Thus, studies of conformational 
changes of large proteins are out of reach for conventional atomistic simulations 
at equilibrium. Therefore, the use of full atomistic models is restricted to relatively 
small systems or short time scales (nanoseconds to microseconds). The clear 
advantage of the atomistic simulation is that the results are detailed and enable 
to study the phenomena which are difficult to access by experimental methods, 
e.g. the lifetime of a single hydrogen bond.  
4.2.2 Conditions in molecular dynamics simulations 
Simulations are usually carried out in the explicit solvent (water), and the water 
molecules are added to fully immerse the system in the box (Figure 15). There 
are many water models available for MD simulations, three-point TIP3P water 
model being the most popular and the one used in this work. The system should 
have periodic boundary conditions, meaning that molecules that exit one side of 
the system will wrap to the other side of it. This is to enable the constant number 
of particles in the simulation box, which is required by statistical mechanical 
ensemble (NVT or NPT), and to avoid finite-size effects. It is important that the 




Figure 15 Simulated protein in a cubic TIP3P water box 
Three input files are needed to start the simulations. These are the topology file, 
the coordinate file, and the force field. The topology file contains all the 
information about the structure and connectivity between atoms in the system. 
A typical MD simulation consists of several subsequent stages, which are outlined 
in Table 7. 
Table 7 Different stages of an MD dynamics performed 
Stage Purpose 
Energy minimisation Adjust the structure to the force field, particular 
distribution of solvent molecules and relaxation 
of possible steric clashes 
Heating (NVT) Linear heating of the system from 0K to 300K 
Equilibration (NPT) Equilibration at constant pressure. Used to 
equilibrate kinetic and potential energies 




4.2.2.1 Energy minimization 
The methods to obtain the protein structure tend to present several atomic 
clashes. Therefore, in order to assure the structural stability of the system, energy 
minimisation is required. If the system energy is too high, the resulting force 
vector will have a momentaneous high intensity, disrupting the simulation box 
and crashing the integration cycle. Energy minimisation consists in an approach 
to reduce the probability of the aforementioned crash. One of the most popular 
methods to reach an energy minimum in molecular mechanics are the steepest 
descent algorithm. Nevertheless, it should be considered that the system might 
get trapped in a local energy well, therefore a more global method to sample the 
global energy minimum might be required. 
The steepest descent (SD)153 algorithm is a method based on the derivative of 
the potential energy. For every minimisation cycle, the 3N dimension position 






Where 𝑟𝑛 is the starting position, 𝐹𝑛 is the force applied in that atom, 𝑀𝐴𝑋(𝐹𝑛) is 
the maximum force applied in any atom and ℎ𝑛 corresponds to the atomic 
displacement for that cycle. For this reason, the process goes through all system 
atoms, and the convergence criteria is either a predefined number of cycles or an 
upper threshold of the system highest force. 
SD is a simple method that tends to be quick. Due to its use of only orthogonal 
gradients, it is prone to get trapped in a local energetic well153. This cause might 
be attenuated by modifying the parameter ℎ (maximum allowed displacement per 
cycle), with a progressive decrease in a series of cycles to improve the final 
configuration. From a biomolecular point of view, the protein’s starting 
configuration tends to be close to the global minimum, since in most cases 
corresponds to a representation of the native state. Nevertheless, issues with the 
experimental data upon resolving its structures may arise erroneous sidechain 
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configurations that energy minimisation should solve. Once the system is 
energetically minimised, the thermodynamic variables need to be defined. 
4.2.2.2 Reaching thermodynamic equilibrium 
In principle, the model obtained after the energy minimisation procedure has a 
temperature of 0K, as there is no dynamical atomic motion assigned to it. 
Therefore, the system temperature must be resolved. A specific condition of the 
experiment should temperature increase. In the case of system heating and NVT 
ensemble is used. 
The NVT ensemble is a statistical ensemble that represents the probability of 
accessible states in a predefined configuration. For this case, the number of 
particles (N), the system volume (V) and the temperature (T) are set as constant. 








Where 𝑘 corresponds to the Boltzmann constant, 𝑇 to the temperature, 𝐸 is the 
state energy and 𝑍 or partition function is (Equation 14): 







As the probabilities in this ensemble are not dependant on any other variable (i.e. 
pressure), this approach can be used for heating the system. Position restraints 
are applied to ensure that this process does not affect the starting structural 
conformation. These restraints tend to be applied through the addition of a 
harmonic potential on selected protein atoms.140 
Next, in order to reach a microstate temperature T in a restrained configuration, 











 =  
𝑘𝑇
2
(3𝑁 − 𝑁𝑐) 
Equation 15 
Where 𝑚𝑖is the mass and |𝑉𝑖|
2 corresponds to the average velocity of atom 𝑖, 𝑁 
to the total number of particles and 𝑁𝑐 to the number of restrained components. 
This corresponds to a Boltzmann-Maxwell distribution of velocities that reaches 
the desired temperature154. To keep the temperature updated through the 
integration timesteps, a thermostat algorithm is applied to the system. A simple 
method to change the temperature corresponds to rescaling the velocity for every 

























And 𝑇𝑖 is the temperature of step 𝑖. These methods do not actually allow thermal 
fluctuations through the system due to the fact that the temperature rescales 
directly with the velocity. Based on the aforementioned feature, the Berendsen 
thermostat was devised. This is an algorithm that assumes that the system is 
weakly coupled to a heating bath, which updates the average temperature. 
Because of the weak coupling, the temperature does not scale directly with 
velocity.154,155 Therefore, 𝛾 for a Berendsen thermostat follows Equation 18. 








Where t corresponds to a coupling term named “rise time”. This term controls 
how strong the system feels the temperature bath. Because scaling methods 
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scale the velocity directly, they do not allow stochastic variations. Other 
thermostats, such as the Nosé-Hoover thermostat address this issue. Usually 
these thermostats demand more computational resources but are able to 
simulate a proper canonical ensemble. An alternative between both methods 
would be velocity rescaling.156 This method, implanted in Gromacs, adds a wiener 
stochastic function to the 𝛾 term. Therefore, the velocity scaling becomes 
randomised, sampling a full canonical ensemble. This thermostat was the one 
used throughout this work. 
4.2.2.3 Pressure equilibration 
Once the system has reached thermal equilibration, the volume configuration 
needs to be set. In an NVT ensemble, the box volume is constant, and this might 
not be the most accurate volume conditions for the box in question. Therefore, 
equilibration is needed to set up the remaining macro thermodynamic variables, 
such as pressure. Furthermore, the experiments we aim to model tend to happen 
in a constant pressure regime.  
In this second stage of equilibration we use an NPT or isothermal-isobaric 
ensemble with N – number of particles, P – pressure and T- temperature as 
constants. For this case the system is coupled to a pressure control as well as a 
temperature bath. The two most typical ways are the weak Berenden coupling153 
and the Parrinello-Rahman barostat157. The Berendsen coupling barostat works 
in a similar manner to its thermostat, as it scales the box volume through time to 
achieve a predefined pressure. This barostat belongs to a class called isotropic 
scaling as it does not change the overall shape of the box but equally modifies 
the size of the box in all dimensions. On the other hand, the Parrinello-Rahman 
barostat performs an anisotropic scaling.  
4.2.2.4 Production simulation 
Once the thermodynamic macro variables are defined and the system is 
equilibrated, the dynamical ensemble can be calculated. As mentioned before, 
the integration cycle drives the calculations. After the equilibration stages, the 
atomic harmonic restraints are disable so the protein system can sample in a 
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more realistic manner. In most cases, the parameters used for a production run 
are the same that for an NPT configuration. 
4.2.3 Variations in classic conditions 
The main aim of this project is to detect new transient or cryptic pockets that may 
be difficult to identify by the use of classical computer-aided drug design (CADD) 
techniques. Modifications in the typical simulation conditions could be exploited 
in the identification of new “druggable” cavities.  
4.2.3.1 The cosolvent approach 
The discovery of novel binding sites is not always coupled to the local minima 
retrieved from the simulated landscape, or the highest-populated clusters. The 
use of small, drug-like “probes” as cosolvents (Figure 16) can be used to assess 
which functional groups would best complement the surface of the binding site of 
interest (either already known or newly identified). 
Several cosolvent dynamics approaches have been developed in recent years. 
Most of these approaches use very small probes such as: ethanol, isopropanol, 
methanol, acetonitrile or acetamide.158  In the present work, the cosolvent based 
framework has been extended to usage of drug-like fragments derived from 
known drugs/inhibitors. The low probe concentration permits to perform longer 
simulations before observing phase separation without the use of repulsive 
potentials. Longer trajectories permit the ligands to search for more cavities, 





Figure 16  Cartoon depiction of a cosolvent simulation. In step 1 cosolvents A (crosses) and B 
(circles) are randomly in a simulation box put in a protein (green) – water (red dots) system. After 
the simulation (step 2) molecules A show a higher affinity to one cavity of the protein and interact 
with it, while B molecules do not interact with the protein at all. 
4.2.3.2 Enhanced sampling techniques 
The energy landscape of a protein is characterised by a series of metastable 
states separated by high energy barriers. Since atomistic MD is limited to a few 
femtoseconds integration timesteps, it is difficult to go into the millisecond 
timescale and beyond with nowadays machines, where these new 
conformational states could be visited.159 Only a few special machines, such as 
Anton or the use of the Folding@home, are able to reach extensive 
timescales.160,161According to the transition state theory, the relationship between 
the timescale of state transition and the height of an energy barrier is 
exponential.162–164 This means that most conformational events of interest, such 
as the folding process of a protein or the binding/unbinding process of a 
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substrate, often occur at a larger timescale.165 In an attempt to overcome this 
issue, a number of enhanced sampling techniques have been developed over the 
past decades to allow for fast thermodynamics and/or kinetics calculations. In the 
next section I will discuss the umbrella sampling (US), since it is the method that 
was used in this project. 
4.2.3.2.1 Umbrella sampling 
Umbrella sampling, developed by Torrie and Valleau64, consists on the 
application of a bias, an additional energy term, to the system to ensure efficient 
sampling along a reaction coordinate. A reaction coordinate (ξ) is a continuous 
parameter that provides a distinction between two thermodynamic states. 
Generally, ξ appears to be defined on geometric grounds, such as distance, 
torsion, or the difference between the root mean square deviations from two 
reference states. If the reaction coordinate of choice is good enough to 
differentiate distinct states, the free energy between these would be calculated. 
This is aimed in different simulations (windows), the distributions of which 
overlap.166 Window 𝑖 bias potential 𝜔𝑖 is an additional energy term that only 
depends on the reaction coordinate (Equation 12). 
𝐸𝑏(𝑟) =  𝐸𝑢(𝑟) + 𝜔𝑖(ξ) Equation 12 
The superscript ‘𝑏’ denotes biased quantities, while the superscript ‘𝑢’ denotes 
unbiased quantities. Quantities without superscripts are always unbiased. 
The reaction coordinate is split into a number of windows to ensure an optimal 
sampling. A bias function is implemented in each of these windows to keep the 
system close to window 𝑖 reference point. A simple harmonic bias of strength 𝐾 
is often used (Equation 13). 
𝜔𝑖(ξ) = 𝐾/2(ξ − ξ𝑖
𝑟𝑒𝑓
)2   Equation 13 
To obtain unbiased free energy 𝐴𝑖(ξ), the unbiased distribution of the reaction 





∫ exp[−𝛽𝐸(𝑟)] 𝛿[ξ′(r) − ξ]𝑑𝑁𝑟
∫ exp[−𝛽𝐸(𝑟)] 𝑑𝑁𝑟
    
Equation 14 
The unbiased probability 𝑃𝑖
𝑢(ξ)can be determined by Equation 15. 
𝑃𝑖
𝑢(ξ) = 𝑃𝑖
𝑏(ξ) exp[𝛽𝜔𝑖(ξ)] 〈exp [−𝛽𝜔𝑖(ξ)]〉   Equation 15 
Biased probability can be obtained from the simulation of each window, and the 
free energy of every window could be calculated by Equation 16. 




𝑏(ξ) − 𝜔𝑖(ξ) + 𝐹𝑖 
Equation 16 
Where 𝐹𝑖 = − (
1
𝛽
) 𝑙𝑛〈exp [−𝛽𝜔𝑖(ξ)]〉 as long as one window covers the entire 
range of ξ to be examined. If the free energy curves are to be combined into a 
global one (Figure 17), 𝐹𝑖 has to be calculated with methods such as the weighted 
histogram analysis method (WHAM)167,168.  
 
Figure 17 Global free energy (black solid curve) and the contributions Ai of some of the windows 
(dashed curves). Only every third window is shown for clarity. At the bottom: the biased 
distributions Pib as obtained from a simulation are shown (coloured solid curves). Relatively few 
bins (100) have been used to generate this scheme166 
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WHAM is applied to minimise the statistical error of 𝑃𝑢(ξ). The global distribution 
is calculated by a weighted average of the distributions of the umbrella windows 
(Equation 17): 


















, 𝑎𝑖(ξ) = 𝑁𝑖 exp[−𝛽𝜔𝑖(𝜉) + 𝛽𝐹𝑖] 
Equation 19 
With 𝑁𝑖 being the total number of steps sampled for window 𝑖. Equation 20 
calculates 𝐹𝑖.  
exp(− 𝛽𝐹𝑖) = ∫ 𝑃
𝑢( 𝜉) exp[−𝛽𝜔𝑖(𝜉)] 𝑑𝜉 
Equation 20 
Since 𝑃𝑢 enters Equation 20 and 𝐹𝑖 enters Equation 17 via Equation 19, these 
have to be iterated until convergence. 
For an efficient umbrella sampling run, an overlap between windows is required 
for WHAM analysis. Good sampling is essential for a proper choice of the reaction 
coordinate. If the reaction coordinate misses important structural changes, it can 
lead to artificial reduction or increase of the energy barriers from the results 
obtained by umbrella sampling. 
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4.2.4 Data analysis 
MD simulations produces trajectories, which are series of sequential snapshots 
of the simulated molecular system which represent atomic coordinates at specific 
time periods. This generates large amounts of data, which must be processed 
and analysed. The type of analysis performed can vary substantially depending 
on the question(s) and hypothesis posed before even carrying out the simulation. 
In the next section, I will outline the analytical techniques applied in this work. 
4.2.4.1 Root-mean squared deviations and root-mean squared fluctuations 
Root-mean squared deviation (RMSD) is the calculation of the average distance 
of certain atoms in a system from a reference structure, 𝑟𝑖
𝑟𝑒𝑓











Where 𝑀 = 𝛴𝑖𝑚𝑖 and 𝑟𝑖(𝑡) is the position of atom 𝑖 at time 𝑡 after the structure is 
fitted to the reference state. RMSD is calculated to evaluate the stability of the 
simulated system. If the obtained RMSD plot shows severe deviations through 
time, then the system has not reached energy convergence, meaning that further 
simulations would be required.140 An example of the RMSD plot is showed in 
Figure 18.a. 
Root-mean square fluctuation (RMSF) is a measure of the difference between 











Where 𝑇 is the time over which one wants to average and 𝑟𝑖
𝑟𝑒𝑓
 is particle 𝑖 
reference location. RMSF is distinguished from RMSD by giving a value for each 
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particle or group, such as an amino acid residue, over time. This means that the 
fluctuation of every particle (residue, atom, chain, etc.) can be evaluated, and 
thus the regions of the system showing large conformational changes can be 
identified.140 An example of the RMSF plot is showed in Figure 18.b. 
 
Figure 18 RMSD (A) and RMSF (B) plots 
58 
 
4.2.4.2 Geometric clustering 
MD simulations can generate thousands of snapshots (conformations) to be 
analysed. In some cases, these conformations can be very similar, and it is of 
interest to reduce the set of conformations for subsequent analysis. Geometric 
clustering is an analysis technique performed to classify different structure 
samples during an MD simulation (Figure 19). There are several clustering 
methods available, but in this work user approached the one developed by Daura 
and coworkers169 (via the gmx cluster module), which is based on the mutual 
RMSD between all conformations sampled during the MD simulation (for a 
specified RMSD cut-off). The generated clusters are mutually exclusive, meaning 
that a structure can only be a member of a single cluster. Geometrical clustering 
is often used to describe the various conformational changes in a protein. These 
structures can also be used for further studies such as virtual screening (VS) or 
umbrella sampling (US) simulations. 
 
Figure 19 Top three clusters from an MD simulation 
 
4.2.4.3 Principal component analysis (PCA) 
Following the idea of the previous section the number of variables that are used 
to describe each conformation is very large. These variables may be correlated. 
Principal component analysis (PCA) is a commonly used method to eliminate 
these correlations and to reduce the dimensionality of the data set. In general, a 
principal component (PC) is a linear combination of the variables. The first PC of 
a data set corresponds to that linear combination of the variables which give the 
59 
 
“best fit” straight line through the data if plotted in a n-dimensional space, 
meaning that it has the largest possible variance (Figure 20). The second and 
succeeding principal components have the highest variance possible with data 
not already accounted by previous principal components. Each PC corresponds 
to an axis in a n-dimensional space and is orthogonal to all other PC. There can 
be as many dimensions as variables the original data set provides, but in an 
optimal situation only a few (3-5) principal components may be required to explain 
most of the data.140 The modules gmx covar and gmx anaeig have been used to 
perform PCA analysis. 
 
Figure 20 Two dimensional PCA plot from an MD simulation. Different clusters of the simulation 




 4.2.4.4 Distances 
Monitoring of distance between two groups of atoms is another way to obtain 
useful information about the system. H-bond formation (or breaking), shifting of 
sidechain unveiling cavities or distance between protein monomers are some of 
the several outcomes that distance measure can provide. 
4.2.4.5 Solvent accessible surface area (SASA) 
In the context of cosolvent MD, it is a matter of interest to evaluate if the 
participation of the cosolvent probes is indeed promoting the formation of new 
binding regions. One way to evaluate this feature may be to calculate the solvent 
accessible surface area (SASA). As its name states, SASA is the surface area of 
a biomolecule that is accessible to a solvent. In this work, the SASA of the 
systems were computed with the gmx sasa module, which applies the double 
cubic lattice method170. 
4.3 Molecular docking 
Molecular docking is a technique used to predict the interaction between a ligand 
and a protein binding site. This technique calculates the most optimal binding 
geometries (poses) and binding energies, by placement of the ligand in different 
orientations and conformations within the binding site, which can be considered 
completely rigid or semi-flexible. Molecular docking attempts to mimic the natural 
course of interactions between the ligand and its cognate receptor.20,140 
There are three important applications of the molecular docking. One is the 
determination of the binding mode (geometry) of a ligand bound to a protein. 
Molecular docking generates hundreds of thousands of putative ligand binding 
orientations/conformations at the defined binding site within the protein target.171 
A scoring function is used to rank these ligand conformations by evaluating the 
approximate binding energy of each of the putative complexes.  
The second application is to identify the potential hits for a given protein target by 
searching large ligand databases, i.e. the virtual screening.172 A reliable scoring 
function should be able to distinguish binder and non-binders and to rank known 
binders the highest.  
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The third application of molecular docking is to predict the absolute binding affinity 
between the protein target and the given conformation of a ligand. This is 
particularly important to the hit-to-lead and lead optimisation.173 An accurate 
scoring greatly increases the optimisation efficiency and saves costs by correctly 
predicting the binding affinities of the modified ligands before the much more 
expensive step of ligand synthesis and experimental testing.  
Most modern molecular docking methodologies consider the backbone of the 
protein target rigid, with partially flexible chains. The more flexibility is considered 
in the process, the more computational time and resources are required. The 
docking procedure involves sampling over many degrees of freedom.  
For each ligand, a certain number of different conformations is generated, 
oriented, fitted, energy minimised, and energy scored. This number is user-
defined, but it may vary from hundreds to many thousands. The number of 
orientations is also user-defined and typically within thousands. The resulting 
binding poses with lower energy scores (more favourable binding energy) are 
selected for further studies.  
To evaluate the energies of binding poses resulting from the docking, scoring 
functions are used. Scoring functions are simplified descriptors of free binding 
energy. The appropriate scoring function would rank the experimentally 
determined binding modes the highest (lowest energy, most favourable).  
Scoring functions can be grouped into three classes: force field‐based, 
knowledge‐based, and empirical scoring functions. Force field based scoring 
functions are developed based on the classical molecular mechanical force fields, 
i.e. physical atomic interactions,174 including van der Waals interactions, 
electrostatic interactions and bond stretching/bending/torsional forces. Empirical 
scoring functions estimate the binding affinity of a complex on the basis of a set 
of weighted energy terms obtained empirically.175 Compared to the force field 
scoring functions, the empirical scoring functions are much faster to calculate due 
to their simplified energy terms. A third kind of scoring functions are knowledge-
based scoring functions, which employ energy potentials that are derived from 
the structural information embedded in experimentally determined atomic 
62 
 
structures.176 Moreover, quantum mechanical (QM) and semi-empirical QM 
(SQM) based scoring functions have been recently designed to capture the 
binding affinity trend and native pose identification.177,178 
To improve the quality of predictions, sometimes a combination of different 
scoring functions is used and weighed to give a new scoring value or rescore 
previous results. (Figure 21). 
Docking is divided into stages, as illustrates in the diagram (Figure 21). For each 
stage, multiple methods are available. 
 
Figure 21 Molecular docking protocol to follow for a regular virtual screening. Dashed boxes 
represent optional steps considering the purpose of the procedure or the software used. 
Despite a large number of comparative studies, it is still impossible to determine 
which programme and protocol are the best. Many studies have shown that 
success in molecular docking depends heavily on a number of factors such as 
the scoring function, the nature of the studied target, input docking and/or the 
metrics used to determine the study success. Comparisons between studies may 
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result in contradictory conclusions.179  In this work, three different docking 
software packages were used: MOE-Dock180, UCSF DOCK181 and AutoDock4182. 
These three packages are a selection of some of the most popular applications. 
Each docking software has implemented its own placement methodology and 
scoring functions which differs from the other to a greater or lesser extent. With 
respect to the most commonly used package applied in this work (MOE-Dock), 
the docking procedure is divided into four main components: ligand-conformation 
generation, optional pharmacophore filtering, ligand placement and scoring in the 
pocket and flexible receptor and ligand refinement with re-scoring. The 
generation of ligand conformations is accomplished by supplying a collection of 
prepared ligand conformations generated using the Conformation Import 
application to the docking engine. The maximum number of outputted 
conformations is set to 10 000 by default. Then, using the MMF94x force field183–
187 the resulting ensemble is energy minimised, and partial charges are assigned 
to the atoms. Using the Triangle Matcher protocol, which defines the active site 
using α-spheres188 similar to the spheres generated in UCSF DOCK (SPHGEN), 
ligand placement takes place. For AutoDock, a Lamarckian Genetic Algorithm 
(LGA) approach is typically used for globe pose sampling.189 The top 1000 poses 
produced from placement are then scored using the London ΔG scoring 
function190 (Equation 23)180: 
∆𝐺𝐿𝑑𝐺 = 𝑐 + 𝐸𝑓𝑙𝑒𝑥 + ∑ 𝑐ℎ𝑏𝑓ℎ𝑏 + ∑ 𝑐𝑚𝑓𝑚 + ∑ ∆𝐷𝑖
𝑎𝑡𝑜𝑚𝑠𝑖𝑚𝑒𝑡𝑎𝑙−𝑙𝑖𝑔ℎ−𝑏𝑜𝑛𝑑𝑠
 Equation 23 
𝑐, 𝑐ℎ𝑏 and 𝑐𝑚 are constants that have been trained over 400 protein ligand 
complexes. 𝐸𝑓𝑙𝑒𝑥 is a topological estimate of ligand entropy. Both 𝑓ℎ𝑏 and 𝑓𝑚 are 
measures of geometric imperfections of protein-ligand and metal-ligand 
interaction. ∆𝐷𝑖 is the desolvation energy term which is approximated using a 
volume integral London dispersion. The top conformations (number defined by 
the user) are kept and minimised using MMF94x within a rigid receptor. The 
resulting poses are the scored using the generalized-Born volume 
integral/weighted surface area (GBVI/WSA dG) scoring function180 in a flexible 









𝑅 ) + 𝐸𝐼𝑛𝑡𝑒𝑟
𝑣𝑑𝑊 + ∆𝐺𝐵𝑖𝑛𝑑




𝑣𝑑𝑊  correspond to the coulombic and van der Waals contribution to 
binding respectively. The electrostatic solvation contribution, ∆𝐺𝐵𝑖𝑛𝑑
𝑅 , is the 
change in reaction field energy upon binding. Reaction field energies are 
calculated using the generalized Born/volume integral implicit solvent model 
(GB/VI)191, which estimates the free energy of hydration as a classical 
electrostatic energy plus a cavitation energy using a volume integral London 
dispersion energy. The ∆𝐺𝐵𝑖𝑛𝑑
𝑛𝑝𝑠𝑜𝑙
 term represents the change in non-polar solvation 
(van der Waals and cavitation cost) upon binding.180  Instead of the double-
scoring process, UCSF DOCK and AutoDock rely on a single scoring process 
with different procedures. In both cases the accessory program GRID192 is used 
to pre-compute the energy interaction between a dummy probe atom and all 
receptor atoms on a 0.3 Å resolution grid within the area of study. Afterwards, 
every ligand pose is evaluated with each own scoring function. AutoDock uses a 
semiempirical free binding energy force field scoring function, while DOCK 6 uses 
a force field based one. The default conditions applied for each methodology are 
summarised in Table 8. 




Scoring Function I Scoring Function II 




AutoDock 4 Scoring Function (semiempirical 
free energy force field) 
DOCK6 Sphere Generation 
DOCK 6 Scoring 
Function 
 
4.3.1 Analysis of the molecular docking results 
4.3.1.1 Cluster analysis 
Hundreds or even thousands of poses can be calculated for a single ligand in 
every docking calculation. In the case of a blind docking experiment, where the 
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binding site is unknown and the whole protein is selected as a receptor, the 
analysis of the molecular docking results can be challenging. Not only 
conformations are evaluated but also their location of binding. A frequently used 
resource to facilitate the analysis is to clusterise the scored conformations within 
an RMSD value (2.0-4.0 Å)182. Most populated clusters mean that the visited 
cavity could be more druggable than its counterparts.  
4.3.1.2 Ligand interactions 
Ligand-receptor interactions are analysed to determine which could be the key 
residues for a good interaction with the receptor, or if the docked ligand shows 
the same interactions as the crystallised one. Such interactions include hydrogen 
bonds, hydrophobic interactions and solvent interactions.193,194 For an easier 
visualisation, some docking software packages like MOE provide a two-
dimensional diagram of the ligand interactions with the receptor residues (Figure 
22). 
 
Figure 22 Ligand interaction map for a TPCA-1 docked conformation 
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 4.3.2 Validation of the molecular docking results 
As mentioned before, the number of molecular docking packages available to 
date is very extensive. The user has many flavours to choose which could lead 
to very different results. Before performing any virtual screening on a protein 
target (with a known binding site) it is general practice to validate the package of 
choice. Molecular docking is performed with the same crystallised ligand in order 
to replicate the crystallographic conformation. If that conformation is between the 
top scored ones, that is an indicator that the applied docking package is likely to 
provide trustworthy results. Decoys (molecules known to not bind in the region of 
study) are often used to evaluate the ratio of false positives that the used docking 
programme could encounter195. 
4.4 MM-PBSA 
The molecular mechanics – Poisson-Boltzmann surface area (MM-PBSA) 
approach is used to calculate the free energy difference between two states, 
typically the bound and unbound state of two solvated molecules, or to compare 
the free energy of two different solvated conformations of the same molecule.196 
The overall objective is to calculate the absolute binding free energy for the non‐
covalent association of any two molecules, A and B, in solution (Equation 25): 
[𝐴]𝑎𝑞 + [𝐵]𝑎𝑞 ⇔ [𝐴
≠𝐵≠]𝑎𝑞
±  Equation 25 
[𝐴]𝑎𝑞 refers to the ensemble of molecule A free in solution, [𝐵]𝑎𝑞  refers to the 
ensemble of molecule B free in solution, and [𝐴≠𝐵≠]𝑎𝑞
±  represents the complex 
formed from molecules A and B, considering any structural changes and the 
solvent reorganisation (aq±) that may occur upon the complex formation. 
Free energy is a state function, meaning that the free‐energy difference 
associated with a given event like a drug binding to its protein target is determined 
only by the energy prior to that event and the energy following it. In other words, 
to calculate the binding free energy of a ligand to a protein, the ligand-protein 
complex, needs to be “compared” to both the ligand and the protein as separate 
entities in the solution. 
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Figure 23 Adapted diagram of binding free energy between of a ligand to a protein196 
However, calculating free energies can usually only be done using small steps 
according thermodynamic cycle (Figure 24)143: 
 
 












0 )  
Equation 26 
In the MM-PBSA approach, different contributions to the binding free energy are 
calculated in the following ways: 
• Solving the linearised Poisson-Boltzmann or Generalised Born 
equation for each of the three states and adding an empirical term 
for hydrophobic contributions, solvation free energies are 






0  Equation 27 
• Obtaining ∆𝐺𝑣𝑎𝑐𝑐𝑢𝑚
0    by calculating the average interaction between 
a protein and a ligand. If necessary, the entropy change upon 
binding is taken into account143 (Equation 28): 
∆𝐺𝑣𝑎𝑐𝑐𝑢𝑚
0 = ∆𝐸𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑚𝑒𝑐ℎ𝑎𝑛𝑖𝑐𝑠
0 − 𝑇 · ∆𝑆𝑛𝑜𝑟𝑚𝑎𝑙 𝑚𝑜𝑑𝑒 𝑎𝑛𝑎𝑙𝑦𝑠𝑖𝑠
0   Equation 28 
Often, entropy contributions are neglected, if only a comparison of states of 
similar entropy is desired, such as two similar ligands binding to the same protein. 
The reason is that the entropy calculations using normal mode analysis or quasi-
harmonic approach are computationally expensive and are associated with large 
errors that introduce significant uncertainty to the results. The average ligand-
protein interaction energies are usually obtained by performing calculations on a 
group of uncorrelated snapshots collected from equilibrated MD simulation 
trajectories.143 Although MM-PBSA is a popular approach to estimate the free 
binding energy of small ligands to biological macromolecules its accuracy is not 
excellent. This method is very sensitive to the solute dielectric constant and 
contain several questionable approximations such as lack of conformational 
entropy and information about the number and free energy of water molecules in 
the binding site.197 There are several benchmarks assessing the performance of 
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this method.198,199 In this work, MM-PBSA has been calculated using GROMACS 





Chapter 5 Development of the Cosolvent Analysis Toolkit (CAT) 
In this part of the work, the focus was on the development of an analysis tool that 
helps the identification of binding hotspots resulting from cosolvent MD. The main 
goal was to design a platform able to identify newly formed sites with a user-
friendly analysis. The result is the Cosolvent Analysis Toolkit (CAT). CAT has 
been designed as an open-source analytical platform, compatible with commonly 
used molecular graphics software packages such as UCSF Chimera and 
VMD201,202. CAT incorporates two types of analysis: identification and ranking of 
the entire ‘hotspots’, and identification and ranking of the molecular fragments 
suitable for targeting those ‘hotspots’. The former serves as a general detector 
and can be readily used to guide structural biology experimental efforts, while the 
latter brings useful information about the inhibitor/ligand design from the 
structure-guided standpoint. 
  
5.1 Scoring function development 
To create a robust analytical method for reliable detection of molecular hotspots, 
the development of a scoring function was required. From a molecular interaction 
standpoint, such scoring function should include three characteristics: calculation 
of the intrinsic interaction energy between the protein and a cosolvent (probe) 
molecule, and two normalizing factors: retention time of the probe at the binding 
site, and the overall depth of the binding site relatively to the protein surface.  With 
this selection of features, we attempt to identify regions with better probe-protein 
interaction as well as other geometrical features that would deem the detected 
hotspot as “druggable”. Therefore, the scoring function per residue can be written 
as follows (Equation 29):  
 𝑆𝑅𝑒𝑠𝑖𝑑𝑢𝑒 = 𝑆𝐼𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑆𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑆𝐷𝑒𝑝𝑡ℎ Equation 29 
 
 To calculate the interaction scoring part per residue in the protein, CAT defines 
a sphere surrounding the geometric centre of each residue (dashed blue circle in 
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Figure 25). Hence, the interaction energy between the protein and every probe 
inside the sphere is calculated. To avoid atomic clashes, softcore potentials203 
were used, as described in Equation 30.  
















Where r is the interatomic distance,  corresponds to the depth of the Lennard-
Jones potential, 𝜎 is the finite distance to the zero potential, 𝐾 is the Coulombic 
constant in kcal/mol , 𝛿𝑙𝑗 and 𝛿𝑒𝑙𝑒𝑐 are the softcore deltas for the Lennard-Jones 
potential and Coulombic potential respectively204. 
Within the assigned sphere, the average number of cosolvent molecules <M> 
inside the sphere can be calculated. From a simulation trajectory with N frames, 
Sinteraction can be calculated as the ratio between the average interaction energy 
though the trajectory and the average number of molecules inside the sphere 
(Equation 31):  
 











For the stability score, which quantifies the retention time of the probe at the 
binding site, the RMSD of the total number of cosolvent molecules  √∆𝑀2 inside 




(< 𝑀 > −√∆𝑀2)
             
Equation 32 
 
Sstability values range from 0 to 1, allowing the highest values for low variance, 




For the third scoring term, which describes the overall depth of the binding site 
relatively to the protein surface, CAT counts the number of protein atoms 
(𝐽𝐶𝑜𝑛𝑡𝑎𝑐𝑡𝑠)  inside each residue sphere (Figure 25), assigning to it a volumetric 
score 𝑆𝐷𝑒𝑝𝑡ℎ. Afterwards, it is normalised to the highest scored residue, to set the 




𝑀𝐴𝑋 < 𝐽𝐶𝑜𝑛𝑡𝑎𝑐𝑡𝑠 >
          
Equation 33 
 
To define the regions, dummy atoms are created for each residue in its 
corresponding centre of geometry, with its respective Sinteraction (Equation 27) 
assigned to it. 
To define binding regions, CAT systematically scans through the protein 
backbone, defining a new spherical region (Figure 25) which clusterises the 
dummy atoms. This “CAT cluster” has a 𝑆𝑅𝑒𝑔𝑖𝑜𝑛 assigned as (Equation 34):  
 









CAT outputs a PDB file with dummy atoms highlighting the areas of interest 
regarding the Sresidue per residue and SRegion per region, ranked from the best 




Figure 25 Clustering scheme of CAT: A sphere is generated per residue, which encapsulates 
shells of interacting comolecules (yellow circular regions defined by the variable Rresidue). 
Afterwards, a secondary clustering region (blue shaded area, defined by the variable RCluster) 
defines close side-chains centres of geometry, resulting in a series of representative clusters of 
interest. 
In this study, values for the electrostatic and Lennard-Jones softcore delta were 
scanned (Appendix). The best result was attained with deltas set to 1 Å. The 
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sphere radius for the residue–cosolvent interaction was set at 8Å, to incorporate 
approximately 3 solvation shells. The clustering sphere radius was set to 5 Å, 
which encapsulated inter Cα distances for different secondary structure motifs.   
5.2 Probe selection 
Five probe molecules: acetamide, benzene, acetanilide, imidazole, and 
isopropanol were chosen based on three criteria. First, the set has a broad range 
of solubility characteristics, going from highly hydrophobic molecules (benzene) 
to more hydrophilic molecules (acetamide). Second, all probes are widely used 
as crystallisation co-factors, probes employed in fragment-based drug discovery 
(FBDD) efforts, and as moieties present in known small molecule ligands. Third, 
it is a set validated in previously reported studies on allosteric hotspot 
mapping47,74,205,206. 
5.3 Benchmark 
To benchmark the method, the aim was to select proteins with reported 
crystallographic structures of their orthosteric binding site with more than one 
reported allosteric site. Furthermore, proteins that have been studied in 
benchmarks including cosolvent methodologies have been taken into special 
account207. After a careful curation, four structurally diverse targets were 
selected: the ligand-binding domain of androgen receptor (AR-LBD), protein-
tyrosine phosphatase 1B (PTP1B), GTPase HRas and cyclin-dependent kinase 
2 (CDK2) with novel allosteric sites recently described43. Benchmark structures 








Table 9 PDB codes of the crystal structures used for our benchmarking, codes highlighted in bold 
correspond to the structures used for the cosolvent simulations 
Molecule Starting structure Benchmark structures 
 





2PIQ, 2PIR, 2PIT, 2PIU, 2PIV, 










1P2T, 1P2U, 1P2V, 3K8Y, 3K9L, 
3K9N, 3RRZ, 3RS0, 3RS2, 3RS3, 
3RS4, 3RS5, 3RS7 
Cyclin-dependent 
kinase 2 (CDK2) 
4EK3 
6Q3C, 6Q3B, 6Q3F, 6Q49, 
6Q48,6Q4B, 6Q4A, 6Q4C, 6Q4D,  
6Q4F, 6Q4E, 6Q4J, 6Q4I, 6Q4H, 
6Q4G, 6Q4K. 
5.4 Results 
An in-depth study of the molecules used to test the accuracy of the CAT scoring 
function and its corresponding ranking has been done in this study. The obtained 
results were directly compared to the FTMap webserver, a robust, powerful and 
widely popular ‘hotspot’ detecting tool47,57. The comparison concluded that the 
explicit solvent/cosolvent interactions and MD sampling were crucial for the right 
assessment of cryptic binding sites, and CAT scoring function reliably detected, 
filtered and correctly ranked “druggable” regions. 
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5.4.1 Androgen receptor ligand binding domain (AR-LBD) 
The androgen receptor is a multimeric DNA-binding transcription factor that 
regulates expression of genes critical for the development and maintenance of 
the male sexual phenotype.210 Through its ligand binding domain (LBD) it binds 
to male steroid hormones such as testosterone, androsterone, or 
dihydrotestosterone; the binding event occurs at the internal ligand binding 
pocket (LBP).207 Furthermore, the presence of auxiliary allosteric binding sites 
has been reported in two of the solvent exposed regions of the protein: at the 
activation function 2 (AF-2) between helices 3 and 4 and at the binding function 
3 (BF-3) close to helix 9.207 (Figure 26) 
The average structure with its respective CAT clusters have been superimposed 
to a series of experimentally-solved structures with bound ligands in orthosteric 
and allosteric regions (Table 9).207 Binding poses of these ligands and their 
corresponding interactions with protein residues have been considered in the 
analysis. CAT detected both allosteric regions with fragments interacting with 
some of the key residues interacting with the crystallised ligands, as shown in 
Figure 26. At the allosteric AF-2 binding site (Figure 26), several highly ranked 
clusters were mapped mainly in helix 3(H3), including key residues K720 and 
V716 involved in hydrophobic interactions with the ligand, as depicted Figure 
26.c. This was consistent with the values of energy scores, as highest-ranked 
clusters in that area corresponded to fragments with hydrophobic/aromatic 
probes such as benzene and acetanilide. The smaller polar probes also detected 
the H3 area, albeit with a cluster rank (Table 10). Probes interacted with R726 
and N727, two very flexible residues that enclosed or open the allosteric pocket. 
As assessed by visual inspection and covariance analysis (Appendix), the shape 
of the pocket considerably varied, tuned by the behaviour of these two residues, 
which acted as gatekeepers. Considering the small size of this binding site, the 
success of detection of this area as a potential “druggable” hotspot was very 
encouraging. CAT identified regions that not only interact with a couple of helix 3 
residues (Figure 26), but with the majority of the residues within this site and 
surrounding sidechains that could contribute to the further pocket opening. The 
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interaction of the probes with helix 4 was not as favourable as with other areas, 
as no highly ranked clusters were found close to it. 
 
Figure 26 Androgen receptor LBD hotspots found by CAT. Clusters have the following colours 
assigned: acetamide – blue, benzene – purple, acetanilide – orange, imidazole – yellow, and 
isopropanol – green. The crystallographic ligand is coloured cyan. A) Panoramic representation 
of LBD domain centred on the AF-2 site compromised around the H3 and the respective top 
cluster given by CAT; B) Panoramic representation centred around the BF-3 region and the 
respective CAT clusters. Simulations with all five probes found the site with a high rank, as 
described in Table 10. For the second site, only acetamide and benzene show high ranks. C) AF-
2 site and its key residues; K720, V716 and H714, that form part of H3, are detected by 
simulations with all five probes. D) BF-3 and its key residues; simulations with acetamide detected 




For the BF-3 allosteric binding site (Figure 26), CAT also gave satisfying results 
when compared with the experimental data. Although there was a higher number 
of CAT clusters in this area, especially around H9, the scoring rank of them was 
worse than that obtained for the AF-2 site. Key residues contributing to the 
binding site architecture, such as R840, Y834, G829 and F826, presented a CAT 
cluster (Figure 26.d). In this case, acetamide was the fragment with the highest 
affinity to the area. Enclosing the site, CAT also detected interactions with the N-
terminal area at F673 and the “gatekeeper” residues from AF-2 site: R726 and 
N727. To summarise, all clusters detected within AF-2 included the majority of 
the residues from this binding site. These residues are listed in Table 10. 












E706, V746, R752, 
F764, H874, F878 
Not found - ✓ 
AF-2 
Allosteric 
I672, F673, V716, 










F826, E829, Y834, 









The crystal structure of the AR dimer has been recently reported,211 where the 
interactions between the AR monomers could be observed (PDB code: 5JJM). 
These interactions are crucial for the DNA binding and disrupting them could be 
a novel way to inhibit the protein. Interestingly, parts of the region involved in 
protein-protein interactions were detected by CAT along the dimerisation 
interface. This validates the applicability of CAT in mapping of novel and unique 
superficial interaction hotspots, which are very challenging to be detected by 
established methods, such as FTMap.  
The only reported AR binding site that was not detected by CAT was the 
orthosteric one. This site, which is a deep pocket binding dihydrotestosterone 
(DHT), was too buried inside the protein core and shielded from the surface for 
the cosolvent molecules to detect it. The opening of this pocket would require 
large conformational changes and thus simulations longer than performed in this 
study. It is very likely that in the timescales required some of the probes would 
undergo phase separation, which is not desirable in CAT analysis and may lead 
to observing artefacts. We believe that the use of repulsive potentials for probes 
in combination with longer simulations would improve the identification of this 
binding spot. 
Comparison between CAT and FTMap outcomes showed some interesting 
results, as the latter covers what CAT misses. FTMap identified the orthosteric 
binding site as a potential druggable hotspot (Table 10), as the highest populated 
clusters were mapped to that site. However, FTMap failed to identify the allosteric 
binding sites: only one sparsely populated cluster is placed at the AF-2 site and 
none at the BF-3 site (Figure 26). Moreover, unlike CAT, FTMap did not identify 
any dimer-forming regions of AR as potential hotspots. Therefore, an apparent 
strength of CAT is to reliably detect the hotspots that are challenging to FTMap. 
5.4.2 PTP1B 
Tyrosine-protein phosphatase non-receptor type 1 (PTP1B) is a negative 
regulator of the insulin signalling pathway. It has emerged as a promising drug 
target for obesity and type II diabetes mellitus212. Numerous potent PTP1B 
inhibitors have been discovered during last years, unfortunately nearly all 
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medicinal chemistry efforts have been hampered by lack of selectivity and 
inhibition of related proteins, especially T-cell protein tyrosine phosphatase 
(TCPTP)212. 
PTP1B orthosteric binding site is formed by three loops: the WPD with W179, 
P180 and D181, a phosphotyrosine (pTyr) loop including Y46, and a Q loop with 
G262213. An allosteric site (BB site) has been discovered by X-ray 
crystallography208, which has paved a new path to design selective PTP1B 
inhibitors. This site is located between helices 3 and 6, and it includes residues 
L192, A193, F196, E276 and F280.208 (Figure 27). Allosteric sites and other 
binding events have been identified by the means of multitemperature 
crystallography, fragment screening, and covalent tethering209. This last study 
included more than hundred crystal structures and different binding events. In this 
study we focused focus in the two newly identified allosteric sites: the allosteric 
197 site, close to the previously known BB allosteric site, and the loop 16 (L16) 
site (Figure 27). 
CAT analysis for the cosolvent MD simulations in the apo/open state (PDB code: 
1XBO) identified both binding sites: orthosteric and allosteric. For the orthosteric 
site, all probe molecules tested interacted with various regions of the site. As 
showed in Figure 27.a and Figure 27.b, imidazole mapped all regions of interest: 
WPD- , pTyr- , and Q- loops. Isopropanol interacted preferentially with the WPD 
loop, while acetamide, acetanilide, and benzene interacted with the pTyr loop 
residues. For the BB allosteric site, CAT placed clusters for all probes except 
imidazole, with clusters centred at the binding site (Figure 27.c). Helix 3 was 
mapped in its entirety, as it was the helix 4 region that comprised the pocket along 
with its key residues. The close proximity of the 197 site to the BB site might have 
induced some bias to to CAT clusters, as both pockets share residues. Although 
both pockets might be included in the same cluster, the 197 site was mapped by 
CAT, mainly by acetanilide and benzene. Interestingly, most of the clusters from 
this pocket included K197, the mutated residue reported by Keedy and coworkers 
in their study on the “drugabbility” of this pocket.209 Regarding the L16 site, CAT 
placed a series of highly ranked clusters close to the binding site, but in direct 
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contact with just one, two, or no pocket residues. Nevertheless, the level of 
mapping was sufficient to determine the area as a potentially “druggable”. 



























R105, D148, K150, Y152, 
Y153, E157, N193, K197 
Acetanilide 4,5,7 
X Benzene 2,6 
Isopropanol 5,6 
L16 K237, K239, S242, I281 
Acetanilide 1 






Figure 27 PTP1B hotspots found by CAT.  Clusters have the following colours assigned: 
acetamide – blue, benzene – purple, acetanilide – orange, imidazole – yellow, and isopropanol – 
green. The crystallographic ligand is coloured cyan. A) Panoramic view centred on the allosteric 
binding sites; B) View centred on the orthosteric binding site. CAT performs well finding and 
scoring the binding site for PTP1B, since 4 out of the 5 probes are able to interact with the site 
residues. Unfortunately, only isopropanol and benzene find the orthosteric binding site, and 
acetamide interact with neighbour key residues. C) BB allosteric binding site and its main 
residues; all probes but acetamide rank cluster in the allosteric binding site, principally 
isopropanol, which shows interactions with N193, F196 and F280. D) 197 site recently identified 
by Keedy and coworkers209 CAT mapped the whole site, including K197. 
As showed in Table 11, FTMap has not been able to identify the allosteric binding 
site, which further validated CAT as an appropriate toolkit to detect the allosteric 
hotspots that are challenging to established methods such as FTMap. The 
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comparison between CAT and FTMAP shows a remarkable performance and 
robustness of the scoring function and the clustering method implemented in 
CAT.  The drug-like small molecule bound at the allosteric PTP1B site reported 
by Wiessmann and coworkers using X-ray crystallography208 showed that this 
binding site is a bona fide “druggable” site which could be used as starting point 
for a structure-guided design, and which has been validated in the follow-up drug 
discovery efforts208. As showed in Figure 27, CAT ranked the clusters at the 
orthosteric site high, yet it was not biased towards deep pockets, being able to 
report all experimentally detected pockets in the top-ranked 10 CAT clusters, 
which included the allosteric site undetected by FTMap. 
5.4.3 Fragment hotspot screening – H-ras GTPase 
The main difference of the three isoforms of the human Ras proteins, H-Ras, K-
Ras and N-Ras, lies within the primary sequence of the hypervariable region and 
its post-translational modifications214. The catalytic G-domains of the three 
respective Ras proteins are highly conserved, with only a 10% average difference 
in primary sequence identity in the C-terminal lobe (residues 87 to 171)215. The 
N-terminal lobe 1 carries the catalytic binding site with all the G-domains 
switches216 (Figure 28). 
The “effector lobe” contains the small molecule binding sites of Ras, including the 
allosteric site consisting of residues R97, D107 and Y137 (denoted as the 
allosteric lobe)217. This allosteric site is connected to the active site in H-Ras by 
helix 3 (H3), one edge of the inter-lobe linker, and one of the switches of the N-
terminal lobe at the other. This is showed in Figure 28. 
Due to the sensitivity regarding the conformational changes of the H-Ras, the 
cosolvent MD simulations prior to the CAT analysis were run only in the “off” state, 
to enable the direct comparison with the reported experimental MSCS (Multiple 
Solvent Crystal Structure) results on the H-Ras46,218. The MSCS showed several 
hotspots formed in different regions of the protein in the “off” conformation. The 
CAT analysis detected several of these hotspots in highly-ranked clusters. 
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Two major ‘hotspots’ were identified for H-Ras: one found in the inter-lobe linker 
region, and another one in the allosteric lobe (Figure 28). Both hotspots involved 
H3 helix, but each of them was situated on either side of the helix. Cluster 1, as 
numbered in the study by Buhrman and coworkers219, was located near to the 
active site, between H3 and switch II, showing R68 and Y96 as the major 
contributors.  Several highly-ranked CAT clusters interacted with cluster 1 
residues, mainly in helix H3. All probes but acetamide interacted with the key 
residues R68 and Y96. Although acetamide did not interact with these amino 
acids, it placed its highest-ranking cluster around a large region of H3. Cluster 2, 
found between helices H3 and H4, mapped to one of the largest hotspots. In this 
case, CAT interacted with both helix 3 and 4, with residues I93 and H94 from 
helix 3 and virtually all residues from helix 4. There were no acetamide clusters 
found around the pocket, which indicated that this region had a low affinity for 
highly polar moieties. Cluster 4 consisted of a pocket in the inter-lobe linker region 
very close to the nucleotide substrate binding site. It was comprised by D30 and 
K147; the latter being a target for ubiquitination on Ras-GTP220. There were only 
two CAT clusters that interacted with the residues from this pocket. Acetamide 
interacted with D30, while imidazole did with K147. Remaining clusters mapped 
to the pockets that overlapped with sites occupied by effector Ras binding (RBD) 




Figure 28 H-ras hotspots found by CAT. The clusters are coloured as follows: acetamide – blue, 
benzene – purple, acetanilide – orange, imidazole – yellow, and isopropanol – green. The 
crystallographic fragment is coloured cyan. A) Panoramic view of the H-ras and the highest 
ranked cluster for each cosolvent molecule. A)  Depiction of Site 3, B) Site 5, C) Site 6 D) Site 7 
and E) Site 8, Following the naming and numbering from Buhrman and coworkers 219. As shown, 
acetamide and benzene performed better than the other three probes, but the combination of the 
five different probes found most of the superficial binding sites and CAT score found the 
interacting residues to different crystallised molecular fragments. 
At the inter-lobe linker region and at the region overlapping with Raf-CRD, CAT 
has mapped cluster 7. Clusters 3 and 6 overlapped with the RasGAP binding site. 
Although CAT mapped all experimentally detected sites, its performance for the 
lower-ranking clusters was worse than for the first two hotspots. Not all the probes 
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interacted with these binding sites. Interestingly, binding sites mapped by MD 
simulations using our most polar probe, acetamide, did not overlap with hotspots 
detected by other fragments (and vice versa). This suggests that putative 
hotspots detected by acetamide might not be druggable, or that they may be very 
small hence not amenable for fragment growth and structure-based ligand 
design.  
FTMap detected only hotspots marked by clusters 1 and 2; both being among 
highly-ranked FTMap clusters (Table 12). On the other hand, FTMap detected 
the calcium acetate binding site221 whereas neither CAT nor MSCS succeeded. 










































































5.4.4 Novel sites prediction on CDK2 
Cyclin-dependent kinase 2 (CDK2) is a serine/threonine kinase that interacts with 
several different cyclins222. It is comprised by two regions known as C and N 
lobes, connected by a hinge, with a significant role in the cell cycle, in the 
transcription regulation223. CDK2 directly acts on the protein expression related 
to the transition from the G1 to S phase of the cell cycle. Hence, it is an interesting 
protein target for cancer drugs. Functionally, CDK2 goes through a consisting 
series of conformational changes to reach an active state. The interlobe region 
interacts with cyclins (preferably A and E), shifting the activation loop (located 
between residues A149 to T165) and subsequently revealing the ATP binding 
site. This allows the phosphorylation of the threonine located in the active site, 
reaching a final active configuration. 
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Recently, CDK2 was used in a novel experimental approach for the identification 
of binding sites called Fraglite43. Wood and coworkers experimentally mapped a 
series of CDK2 allosteric sites using halogenated fragments expressing paired 
hydrogen-bonding motifs, improving the assessment on its allosteric 
“druggability” and tractability. The method reliably identifies drug-like interactions, 
which are detected by X-ray crystallography, exploiting the anomalous scattering 
of the halogen substituent. The study reported a set of five regions with known 
fragment binding.  
To further assess the capacities of the CAT scoring function, cosolvent dynamics 
runs were carried out with all five previously used probes. This methodology could 
be used with the FragLite probes, CAT analysis can be performed with any kind 
of small molecule probe, but the purpose of this methodology is also to design a 
series of optimal conditions for an orthogonal workflow. Since most of these sites 
were only recently discovered, these serve as the evidence for non-biasing of the 
scoring function developed in this study. CAT analysis ranked all 5 novel fragment 
binding sites43 along with the ATP binding site. Detected hotspots are shown in 
Table 13. 
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Site 2 was located exactly in the activation loop. CAT highlighted all residues 
comprising this loop, including T160, with overlapping clusters of several different 
probes (Figure 29). T160 goes through a phosphorylation event, being one of the 
main contributors of binding site stabilisation224. The region along site 3 
represented the dimerisation area where the binding of cyclin occurs, being found 
by CAT with different cluster ranks. Protein-protein areas were commonly 
highlighted by CAT scoring function, given the calculated energetic aspect which 





Figure 29 CDK2 hotspots found by CAT. The clusters are coloured as follows: acetamide – blue, 
benzene – purple, acetanilide – orange, imidazole – yellow, and isopropanol – green. The 
crystallographic fragment is coloured cyan. A) Panoramic view of CDK2 and the highest ranked 
cluster for each cosolvent molecule. A)  Depiction of CDK2 and highest scored clusters, B) 
Orthosteric site, C) Site 1 D) Site 2 E) Site 3 F) Site 4 G) Site 5. As shown, acetamide and 
acetanilide performs better than the other 3 cosolvent molecules, given the nature of the 
experimental X-ray mapped crystallographic binding regions. Site 4 and 5 in specific shows high 
ranked clusters for these 2 probes, given by the high polarity of the site sidechains. 
Sites 4 and 5 were located in the C-Lobe region. Site 4 was directly related to the 
C-lobe loops and it is a novel binding site for CDK2. It interacted with polar 
residues (such as T221 and R245), which explains its high affinity for acetanilide.  
When constrained, this region can change the dynamics of the semi-unstructured 
T221-D247 C-Lobe loop, which is related to the cyclin dimerisation stabilisation 
event, resulting in a plausible site for structured based drug design.  
Site 5 was found at the end of the α-helical bundle that comprised most of the C-
lobe sequence (Figure 29). It was highly ranked in CAT, particularly for highly 
polar probes, such as acetamide and acetanilide. As described by Wood and 
coworkers, fragments used in their study should be tailored to accurately find a 
specific binding region by the usage of fragments prone to form hydrogen-
bonding interactions. Hence, the used structures should represent highly specific 
interactions, resonating with the results given by CAT, which ranked polar probes 






Chapter 6 STAT3 
Signal transducer activator of transcription 3 (STAT3) protein has emerged as a 
prominent target in tumour progression due to its pivotal role in cell signalling. 
The activation of STAT3 has been related to drug resistance225, the expression 
of anti-apoptotic proteins226, and the inflammatory processes in tumour 
development, among others80,227,228. In spite of its importance in cancer 
progression, the pharmacological targeting of STAT3 by small molecule inhibitors 
is still in infancy. Due to its tendency to aggregate, STAT3 structure determination 
is a major hurdle that prevents structure-guided design based on STAT3 structure 
in both monomeric and dimeric forms, as well as bound to an inhibitor92,94,95. 
Although many strategies have been described in literature to inhibit STAT3, a 
few inhibitors are still going through clinical trials (e.g. TTI-101 [ClinicalTrials.gov 
Identifier: NCT03195699] or napabucasin (BBI-608)126,131,132[ClinicalTrials.gov 
Identifier: NCT03647839]) and STAT3 has become one of the most challenging 
cancer-related protein to target by small molecule, due to its inconclusive ligand 
binding nature. Gaining insights into the atomistic level structure and dynamics 
of STAT3 permits the identification of small molecule binding sites and structure-
guided development of novel therapeutic strategies targeting STAt3 and 
modulating its oncogenic pathways.  
The SH2 domain has traditionally been the main target for drug design, mostly 
accompanied by computational studies relying on molecular docking calculations 
or similar structure-based approaches100,101,108,110,113,118,124,229,230, despite no 
crystallographic data available up to date to support them. These ligands attempt 
– albeit with limited success - to compete with p-Y705 at the binding site known 
for the binding of the phosphorylated residue.111,231OPB-31121127 and OPB-
5160231, are at the time of writing this dissertation, the only two ligands described 
as SH2 inhibitors that bind in a different pocket than p-Y705127,227. Furthermore, 
STAT3 can undergo other post-translational modifications besides Y705 
phosphorylation such as S727 phosphorylation232,233 or K685 acetylation234 and 
it has been experimentally demonstrated that unphosphorylated STAT 
monomers can  dimerise and bind to DNA.234 These allow STAT3 to overcome 
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inhibition targeting SH2 domain, and contributes the explanation of limited 
success of ligands binding to the SH2 domain.  
This chapter describes the evaluation of STAT3 “druggability” with special 
interest in the SH2 and DBD domains. MD simulations and molecular docking 
were performed for the SH2 domain to evaluate its stability and conservation, that 
would deem it as an optimal binding site. The application of umbrella sampling 
(simulations), relationships between inter-domain mutations and binding of a 
potent ligand, BBI-608, in order to decipher the mode of action of the ligand.  
6.1 Is SH2 the ideal site to target? 
For the past years, STAT3 inhibition has been focused on its dimerisation 
process. STAT3 monomers are activated via a peptide (PY*LKTK)111 that induces 
the dimer formation and, for the past years, the modus operandi for STAT3 ligand 
design relied on the search of small molecules competing with this peptide. 
Several candidates have been proposed, but only a few of them have made it 
through the preclinical testing. Low specificity and activity was the main issue for 
these compounds to not go further. This raises the questions on (i) whether 
STAT3 SH2 domain binding site is the best site to target, (ii), whether alternative, 
allosteric binding sites exist in the SH2 domain, and (iii) whether other STAT3 
domains would be feasible for targeting by small molecules.  
6.1.1 Molecular dynamics of the SH2 domain and its “druggability” 
A series of equilibrium molecular dynamics (MD) simulations of SH2 domain have 
been carried out, to study the intrinsic dynamics of this domain, with the focus on 
the pTyr binding site (residues K591, R609, S611, E612, S613). Five 100 ns 
replicas were performed. 
Simulation data showed that SH2s pTyr binding site is highly flexible and 
conformationally adaptive, as key residues from the β-sheet that form the SH2 




Figure 30 Surfaces of the SH2 domain. A) corresponds to the SH2 crystal structure while B) 
shows the three most populated clusters for each of the replicas simulated 
To assess the “druggability” of the obtained SH2 ensemble, FTMap, a well-
established pocket detection tool is used. The most populated cluster for each 
replica has been selected in order to identify the stable binding pockets. 
Interestingly, the modified cavity generated around the phosphorylated pTyr 
residue has not been identified as “druggable” by FTMap (Figure 31) in favour of 
other regions of the domain. These results indicate that the pTyr binding site 
might not be as “druggable” as previously thought. Due to the lack of ligand-
bound crystal structure, CADD approaches focusing on the pTyr binding site 
could be wrongly biased and massively improved if more stable conformations 
obtained by MD are used for drug discovery methods such as virtual screening. 
Since there is no experimental evidence for the direct binding of most of the 
described SH2 inhibitors, there is the possibility that they bind to another cavity 
within the SH2 domain (or elsewhere). Collectively, MD simulations show the 




Figure 31 FTMap results for the SH2 domain. The crystal structure and five different MD replicas 
have been calculated. Fragments in sticks correspond to the mapped areas by FTMap. In orange, 
the surface region corresponding to the pTyr site residues. It can be seen how after MD, FTMap 
does not deem the pTyr site as a “druggable” pocket in favour of other regions of the domain. 
 Some of the sites predicted by FTMap agree with the sites mapped by 
AutoDock4 and DOCK6 from the molecular docking benchmark (see section 
4.2.1.2). The site predicted by AutoDock4 (Site A) is situated just below the P site 
between residues I634 and P639 for one pocket and I 652 and I660 for the second 
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while the one predicted by DOCK6 (Site B) is situated just behind the P site, 
interacting with residues like Y584, E593 and L606. The proximity of these 
cavities to the P site might be causing the movement of near residues, closing 
the P site and therefore inhibiting its activation. Backbone RMSD between the 
crystal structure and MD clusters are calculated, showing a considerable 
difference between the initial and simulated structures. Furthermore, RMSD 
between the simulation clusters are also considerably high (>5Å in most cases), 
indicating the flexibility of the domain (Figure 32.b). RMSF analysis showed high 
fluctuation of pTyr. Upon comparing all runs, some of the residues with a higher 
difference between each other are the ones that form pTyr binding site or close 
companions (Figure 32.a). 
 
Figure 32 A) RMSF per residue for every SH2 MD simulation B) RMSD comparison between the 
SH2 domain crystal structure and the main cluster for every MD simulation 
6.1.2 Molecular docking 
Several of the STAT3 inhibitors described in the literature have been discovered 
via virtual screening (VS). This means that a database of tens of thousands of 
compounds has been tested computationally to a target via molecular docking. 
Typically, validation is performed to verify the applicable scoring function for 
molecular docking. This means that, if possible, molecular docking is performed 
with the crystallised ligand to reproduce the native binding mode, which serves 
as the direct validation of the docking procedure. In the case of STAT3, there is 
no ligand-bound crystal structure available, meaning that the direct validation of 
the docking procedure is not possible. In most cases, it cannot be certain, though, 
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whether the reported STAT3 inhibitors truly bind at the pTyr site, given the lack 
of experimental data for holo STAT3.  Usage of the pTyr activation peptide could 
serve in the validation, unfortunately, peptide docking requires parameters not 
available in scoring functions developed for the most commonly used small 
molecule docking packages. 
In order to validate the STAT3 docking results another, indirect approach was 
used in this study. A virtual screening of the series of STAT3 inhibitors denoted 
as “direct inhibitors” (believed to bind to the pTyr site) was performed, using three 
different docking programs, employing different scoring functions: MOE-Dock, 
AutoDock4 and UCSF DOCK6. Rather than focusing solely on the pTyr binding 
site, the whole SH2 domain was considered to be the target. Convergence of the 
results obtained by different scoring functions would be a viable strategy for 
boosting the confidence in the results, in the absence of structural data. 
The obtained results were heavily dependent on the docking software and the 
scoring function used, as each of the three docking packages identified different 
regions of the SH2 domain as the main binding site (Figure 33). Only MOE 
identified the pTyr binding site as the most populated and highest scoring cluster. 
While AutoDock4 selected a region adjacent to the pTyr site, formed by residues 
Q635 to E638, T714 to T717, K626, I658 and V667 DOCK6 picked the back of 
the SH2 domain as the most likely “druggable” site. These results indicated that  
the outcomes of virtual screening are heavily biased by the method chosen (e.g. 
scoring function), and defining the mechanism of action (i.e. binding mode) of 




Figure 33 Molecular docking results vary depending on the software used. From a set of 
described inhibitors A) Autodock4 identified a region below the pTyr site while B) UCSF DOCK6 
conformations bound preferentially at the back of the domain (pTyr site highlighted in red) 
Considering the high flexibility of SH2 domain and large conformational changes 
within it observed during MD simulations, molecular docking has been 
subsequently attempted, using the newly obtained conformations. The most 
populated cluster of each simulation run (0,20 nm cut-off) from section 6.1.1 has 
been used as its corresponding receptor.  
Figure 33 shows poor “druggability” ofthe pTyr site, and a strong preference of 
other regions of the domain. Unlike in the previous calculations, the results 
obtained by all docking programmes and different conformation were highly 
consistent.  The highest scoring position and most populated clusters were the 
same for all the used scoring functions employed. The procedure identified two 
putative binding sites (Figure 34). 
The results indicate that these two sites have different preferences regarding the 
chemical structure of the ligand. Smaller and planar ligands, containing two or 
more aromatic rings, bind preferentially in an area below the pTyr site (Figure 34). 
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This site, denoted as Site L, forms a deep cavity due to the loops that comprise 
it. High flexibility of these loops (observed during MD simulations) make this site 
transiently open and close. Larger and more flexible ligands bind preferentially to 
the site denoted as Site P, located the opposite side of the SH2 domain, where 
interactions with the linker domain may occur (Figure 34). Potency of these 
ligands is poor (micromolar level), and none of them have made it to clinic. These 
ligands were specifically designed to bind in to the pocket which they could not 
interact with, resulting in a poor affinity. 
 
Figure 34 After MD simulation molecular docking binds known inhibitors in the depicted two areas 
instead of the pTyr site 
6.2 If you cannot win them, join them 
Experimental data have demonstrated that point mutations in the linker domain 
suggest contacts with both the DNA-binding and SH2 domains, which could 
cause structural changes that severely affect STAT3 activity138. Alanine scanning 
demonstrated that the modification of interdomain hydrogen bonds can produce 
a significant decrease (i.e., K551A, W546A) or increase (D570K) in the 
STAT3−DNA-binding compared to that in the wild-type protein138. Understanding 
the effect of point mutations on STAT3 activity at the atomistic level could provide 
significant information about novel binding sites, unveiling new ways to target 
STAT3 by small-molecule ligands. 
6.2.1 Equilibrium MD simulations 
In the study by Mertens and coworkers, several mutations were indicated as 
crucial to control DNA retention time within its respective binding cleft at STAT3138. 
These mutations occurred either in DNA-binding domain, or in the inter-domain 
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region. To evaluate the DNA-binding in the mutated-STAT3, three replicas of 50 
ns MD simulations were performed to equilibrate the STAT3-DNA complexes prior 
to umbrella sampling (US) simulations, and to assess any differences between 
WT and mutants, in respect to their structures and dynamics. Systems have been 
studied for that amount of time based on work by Husby and coworkers, which 
claimed to achieve an energetically conserved and stable simulation.235 The 
results obtained in this work agreed with the published data235, as one of the 
STAT3 monomers was more flexible than another monomer. RMSD variations 
were pronounced mainly in the loops of SH2 and Coiled-Coil (CC).  
 
Figure 35 MD simulations show conformational changes between WT (blue) and D570K (red) 
STAT3 dimers systems. In the D570K mutant, one of the monomers is shifted (B), changing the 
conformational landscape of the dimer. Panel C) shows how the position of the DNA duplex is 
shifted downwards in D570K mutant compared to WT. 
One of the most significant configurational changes occurred within D570K 
mutant, as the DNA double helix shifted downwards (Figure 35). This was most 
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likely caused by the electrostatic effects at the residue located in the interface 
between linker and DNA-binding domain. The modification of the side chain 
charge from negative (D) to positive (K) increased favourable protein interaction 
with the negatively charged nucleic backbone. This tightened the DNA binding, 
resulting in a higher average DNA RMSD when compared to the crystal structure. 
It strongly indicates that the end-point configurations of the protein-DNA 
complexes play a significant role in their binding free energy, since the protein-
nucleotide interactions change significantly between different mutants. 
 
Figure 36 Protein A) and DNA B) RMSD after 50 ns of MD simulation. D570K (brown) mutation 
shows higher RMSD in both protein and DNA counterparts, compared to the other mutations and 
WT-STAT3 
Next, I assessed whether the conformational changes induced by D570K 
mutation were observed in other mutations. Figure 36 shows root-mean-square 
deviation (RMSD) plots of all STAT3 considered in this study as well as WT 
protein. The obtained RMSD values are considerably high, but it should be taken 
into account that the STAT3 dimer is modelled. This leads to the observation of 
the displacement of one monomer, reason of that high RMSD along with the 
modelled loops in the CC domain. The STAT3 dimer is thought to be a mirrored 
image of every monomer, but these simulations indicate a different result. Except 
D570K, there were no large differences in protein RMSD between the mutated 
STAT3 dimers and WT. This gap between D570K and other mutants was likely to 
arise from the combination of electrostatic and steric effects (all other mutations 
replaced large and polar residue with smaller and apolar alanine), which affects 
intrinsic dynamics of the CC domain. Hence, the dynamics of the CC domain 
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might “tune” DNA-STAT3 interactions by allowing adjacent SH2 and DBD 
domains to improve their structural “fit” to the DNA.  
6.2.2 Umbrella Sampling (US) simulations 
To follow up on the effects of the mutations which control DNA retention at the 
STAT3 on the structure, dynamics, and energetics of STAT3-DNA complexes, I 
carried out a set of umbrella sampling (US) simulations, where DNA has been 
pulled from STAT3 dimer. This process was carried out using a series of US 
windows and simulated for 10ns each. We understand that the simulation time 
per window is short for this technique and it will struggle at the moment of 
evaluating convergence and presumably provide a series of energy values 
biologically impossible. Our main interest for this analysis is the comparison 
between the different mutated systems and the profiles they can provide. At no 
point we presume that the obtained values will be representative. 
The potentials of mean force (PMF) calculated via weighted histogram analysis 
method (WHAM) were consistent with the results reported by Mertens and 
coworkers14 in most cases. Experimental results showed a drop in DNA-binding 
for the tested inter-domain mutations (EE434/435AA, W546A and K551A) 
through time and an extraordinary high retention time for D570K, with a 100% 
DNA-binding even after two hours.138 The WT STAT3 had a higher energy barrier 
to reach its unbound state in comparison to W546A mutant (Table 14). The mutant 
showed a lower retention time, which indicates that inter-domain interactions 
between mutated residues and E434 are crucial for STAT3-DNA binding. 
Therefore, disrupting these interactions could represent an attractive strategy to 
target STAT3 by small molecules. K551A shows a similar profile than W546A but 
presented a higher PMF value than the other mentioned and a few kcal/mol more 
than WT (Table 14). 
Consistently with the results of the equilibrium MD simulations, PMF showed 
that D570K binding affinity to DNA was more favourable than of any other mutant, 
and more than WT STAT3 (Table 14). This indicates that this mutation promotes 
a very tight binding between STAT3 and DNA, with a higher energy gap for DNA 
release upon pulling (Figure 37). The PMF curve showed that DNA pulling from 
D570K required a higher energy gap to release DNA from the STAT3 dimer. 
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Experimental retention time correlated with the simulations when compared to 
WT STAT3. The data showed that DNA binding to the D570K was persistent 
through time, it did not drive transcription and resisted dephosphorylation, thus 
prevented STAT3 to exert its function138.  
Collectively, these results indicate that D570K promotes a very tight DNA 
binding, so much that the bound duplex stays “locked” between the dimers, which 
effectively inhibits STAT3 by preventing it from releasing DNA and exerting its 
function as a transcription factor. 
 
Figure 37 Potential of mean force (PMF) of dissociation of DNA from the STAT3 dimer. Both 
K551A (orange) and W546A (pink) mutants showed a lower PMF than WT (violet). EE434435AA 
(light green) would have displayed similar results, but the interaction between DNA duplex and 
DBD of one STAT3 monomer in the latest sampling windows resulted in higher PMF value than 
expected. In comparison, D570K (marine green) showed much higher PMF value than WT, 
indicating that DNA-protein interaction is more favourable in this mutant, relatively to WT. The 






Table 14 Free energy change calculated for all umbrella sampling (US) calculations 








The only discrepancy between these results and experimental data was 
observed for the EE434/435AA double mutant. In the simulations, the mutant 
showed a higher PMF value than WT, which indicated that its DNA binding affinity 
should be higher, while experimental data showed that its behaviour resembled 
that of K551A and W546A mutants, which have shown a considerable drop of 
DNA-binding through time. Analysis of the final US windows indicated that the 
middle of the DNA duplex interacted favourably with the DNA-binding domain of 
one STAT3 monomer, but not another.  Therefore, the US curve of EE434435AA 
mutant displayed higher values arising from these interactions (DNA-STAT3 
monomer) rather than from favourable interactions DNA-STAT3 dimer, as it was 
for D570K mutant. 
The results by Mertens and coworkers138 are based on 60 to 100 min 
experiments that evaluated the percentage of DNA-binding of STAT3. This 
process would include several STAT3 molecules that would most likely go 
through several mechanistic cycles. Therefore, it is plausible that I did not sample 
the conformations that are contributing to these results. As expected, the 
obtained energy values are far from what it should be expected for this system. 
But the size of this system along with the available computer power and time 
impedes the desired further sampling for it. Therefore, as mentioned before, we 
pretend to interpret these values more as a comparison/estimation between the 
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studied systems rather than an absolute indicative of the energy profile of the 
system. 
All simulations indicated significant conformational changes of the arginine 
R414, which were required to release DNA (or to allow the DNA binding to the 
STAT3 dimer). R414 has been shown  as one of the main residues for DNA 
identification and binding235, but it was not described as a “gatekeeper” residue.  
R414 is at close distance from DNA and its initial position did not allow the DNA 
exit from the dimer. By acting as a “gatekeeper” of DNA binding (Figure 38), R414 
exerted a key role in controlling opening and closing of STAT3 dimer, as well 
tuned the dynamics of STAT3 monomers by modulating intra-domain DBD-SH2, 
CC-SH2, DBD-LD, and CC-LD interactions.  
 
Figure 38 Conformational changes of arginine R414 observed during the simulations. Evolution 
of the DNA duplex and R414 position over the simulation time is depicted by colours, from red to 
white. Along the DNA pulling pathway from the STAT3 dimer the R414 sidechain rotates, allowing 




6.2.3 Inhibition of STAT3 by napabucasin (BBI-608) 
The results of simulations of apoSTAT3 (WT and mutants) highlighted a set of 
inter-domain residues, explaining their effect on STAT3 behaviour and function at 
the atomistic level of detail. These observations may pave the way to novel 
strategies for STAT3 inhibition using small molecule ligands.  
 
Figure 39 The binding pose of BBI-608, according to the data reported by Ji and coworkers133. 
Since the crystal structure has not been released, I have modelled the most plausible binding 
mode by molecular docking. The side chain of the mutated K570 residue is displayed and 
coloured green – it is overlapping with the plausible location of BBI-608. 
Recently, Ji and coworkers reported that napabucasin (BBI-608), which is a 
STAT3 inhibitor in advanced clinical trials (Phase 3), binds to a small pocket 
between the linker and DNA binding domain in a STAT3 crystal structure133. 
Since the crystal structure has not been released to the public domain, I have 
assessed the druggability of this segment of STAT3, identified the putative 
pocket, and subsequently built the model of BBI-608 bound to STAT3 using 
molecular docking approach, and subsequently validated the obtained binding 





Figure 40 A) Interatomic distances between the Cα of residues Q344 and G432 and residues 
T412 and Q344, calculated along a 50ns MD simulation of ligand-STAT3 complexes. Replica 1 
(blue) consists in the dissociated system and both Replicas 2 and 3 (orange and green) keep 
their ligand bound through the whole simulation B) Close-up and C) panoramic view as STAT3 
dimer closes once the BBI-608 molecule is bound D) Protein-ligand energy interaction for both 
BBI-608 molecules interacting with each monomer along a 50 ns MD simulation (three replicas: 
blue, red, and green). STAT3 dimer bound to DNA (black) is showed as the reference. 
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Molecular docking was performed by MOE for each STAT3 monomer 
separately, in an attempt to generate the most plausible conformation relying the 
limited data available. Both blind (whole monomer) and targeted (residues of the 
identified pocket) docking calculations resulted in a set of conformations with 
favourable energy scores and highly-populated cluster located within the DBD 
site pocket, in close contact with residues H332, P333, R335, K573 and D570 
(Figure 39). Two conformations, matching the published data, were found: both 
were assessed and validated. 
To validate the binding mode of BBI-608, MD simulations of WT STAT3-DNA-
BBI-608 complex were performed for 100 ns in triplicate. Subsequently, the ligand 
affinity has been calculated. The ligand docked either of STAT3 monomers 
remained bound through the whole simulation. Interaction energies, calculated 
by MMPBSA analysis (g_mmpbsa200 module) resulted in -18.1 ± 2.6 kcal/mol, 
showing a favourable binding. 
US simulations, performed using the same protocol as for STAT3-DNA 
complexes, started the pull from the most populated cluster. The calculated 
binding affinity has been severely overestimated (-160 kcal/mol), nevertheless it 
showed very tight binding. It is obvious that these values are completely 
unthinkable and therefore the experiment was replicated with similar results. 
Much longer sampling is required for this system to reach convergence and 
obtain a proper picture of the energetic profile of the system, but we believe that 
even so there is a correlation between the studied systems. Compared with the 
results obtained for protein-DNA complexes described in the previous section, it 
implies that the presence of BBI-608 enhances DNA binding with a similar effect 
to D570K mutation. As such, BBI-608 inhibits the function of STAT3 in a similar 
manner to D570K mutation, which does not drive transcription and resists 
phosphorylation12. Since D570 has been annotated by Ji and coworkers133 as the 
BBI-608 binding site residue, we concluded that BBI-608 binding to WT STAT3 
generated a similar DNA-protein interaction pattern and retention time than 
D570K mutation. 
Next, I performed MD simulations of BBI-608-bound WT STAT3 dimer without 
DNA, to study the influence of the ligand on the protein behaviour in the absence 
of DNA. BBI-608 was bound to each STAT3 monomers and four 100 ns replicas 
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showed a variation of results. In only one out of the four replicas, both BBI-608 
molecules remained bound in their pockets through the whole trajectory, while 
DBD domains of both STAT3 monomers moved closer to each other, reaching 
the point of forming inter-domain hydrogen bonds. In one simulation both ligand 
molecules dissociated from the pockets, which caused an opening of the STAT3 
dimer and in the other two simulations one of the ligands left the binding cavity at 
the 35 and 70ns of MD simulations, while another remained bound to STAT3.  
To assess ligand-induced conformational changes within the DNA entry through 
both DBD domains, distances between some of the residues involved in H-
bonding (e.g. Q344-G342 and T412-Q344) were measured and analysed in all 
four replicas and compared to the simulation of the WT STAT3 dimer without DNA 
and/or BBI-608 bound (Figure 40).  
STAT3 dimer closed further down in the presence of BBI-608. This was 
particularly pronounced in one of the replicas, in which the distance between 
monomers reduced to <5 Å. These results indicated that BBI-608 binding to 
apoSTAT3 is likely to trigger conformation changes that would prevent DNA from 
binding. In the replica simulation, where both ligands dissociated from STAT3, the 
distance between monomers increased upon ligand dissociation, as both ligands 
exit via the gap formed between DBD domains of STAT3 monomers.  
Protein-ligand interaction energy was calculated and a correlation between 
ligand dissociation, dimer separation and poor ligand affinity was observed.  
The simulations also indicated that ligand binding to one of the STAT3 monomers 
is more favourable than binding to another one. Although interaction energies are 
favourable for both monomers, one showed an interaction energy value twice as 
favourable as for another monomer. Although the allosteric effects within STAT3 
were beyond the scope of this study, these results strongly suggest that such 
effects may occur in STAT3 dimers and contribute to the modulation of STAT3 
by inhibitors. Another explanation could be that the model was not optimal. 
Although the used docking poses have an extraordinary resemblance to Ji’s 
data,133 only one is shown in the patent. Since this dimer is asymmetric, DNA 
interactions with both cavities would be different and could imply a different 
conformation and/or location for the ligand that does not correspond to the model 
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one. Furthermore, the MD results strongly indicate that one monomer is much 
more mobile than the other, and this is likely to affect protein−ligand affinity. 
 
Figure 41 “Druggability” of STAT3 dimer. Sitefinder A) and fpocket B) were used to identify new 
potential pockets for structure-based drug design. In both cases the BBI-608 DBD site was 
identified along with novel DBD pockets. 
6.2.4 Identification of a novel “druggable” binding site 
Experimental results12 combined by the simulations strongly indicated that 
targeting the interface between STAT3 monomers may trigger similar response 
to the inhibition by ligands binding to the DBD domain, and therefore be explored 
in structure-based ligand design efforts. With most STAT3 ligands being designed 
for the SH2 domain and just a few for the DBD domain, the identification of new 
“druggable” pockets for STAT3 inhibition is of a great interest. 
As such, I scanned STAT3 for the presence of potential binding sites with two 
pocket detection tools: fpocket55 and MOE’s Site Finder. Upon selection of the 
dimer model and different clusters from its MD simulation trajectories I confirmed 
the binding site identified for BBI-608133, which has been identified by both tools 
as their top-ranked site. Interestingly, that site was detected by both fpocket and 
SiteFinder for all analysed structures (Figure 41). In addition, a new pocket within 
DNA binding domain (close contact with E434 and E435) was identified. The main 
difference between results obtained by both tools is that fpocket was more prone 
to detect SH2 domain sites as pockets (Figure 41, panels B2 and B3) while 
SiteFinder identified a novel “druggable” pocket close to R414 (Figure 41, panel 




6.3 New site, new opportunities 
The identification of the DBD groove as a binding site “druggable” by small 
molecules provided two outcomes relevant for the STAT3 structure-based drug 
design: (1) ligand binding outside of the SH2 domain is possible, and (2) there is 
a specific pocket to be scrutinised. Most of the computationally designed STAT3 
inhibitors were intended to target the pTyr site at the SH2 domain. Targeting the 
new DBD pocket would require a set of different features in order to optimise the 
potency and selectivity. Since there is only one ligand identified to bind to that 
pocket (BBI-608), I used SBDD techniques to explore this pocket and to discover 
new inhibitors.  
6.3.1 Drug repurposing 
Since de novo design is inherently time consuming and its application would be 
beyond the scope of this project, I screened a set of FDA approved drugs 
(repurposing). For the validation, both a blind docking including linker and DBD 
domains, and a DBD-targeted docking have been performed. Considering the 
success in application of MOE in deconvoluting of the BBI-608 binding mode, I 
applied the same protocol in the repurposing study. Out of the whole database236 
(1930 molecules), a series of non-steroidal anti-inflammatory drugs (NSAIDs) 
scored the highest in meeting the selection criteria based on the binding energy 
(score) and ability to reproduce protein-ligand interaction (K573) and 




Figure 42 A) Overlap between most favourable conformations, ligand interactions maps of BBI-
608 (B), ibuprofen (C) and naproxen (D) 
From the series, six ligands were selected for the further evaluation: carprofen, 
fenoprofen, flurbiprofen, ibuprofen, naproxen and suprofen (Table 15). 
To validate the predicted binding modes, molecular docking calculations were 
followed-on by equilibrium MD simulations. Simulations were performed for 100 
ns in triplicates, and the binding affinity was calculated using MM-PBSA. 
Fenoprofen and suprofen had poor interaction energies and they dissociated 
from the binding site during the simulation. The other ligands formed stable 
complexes and their interaction energies calculated by MM-PBSA 
(g_mmpbsa200) showed an excessively favourable binding, with predicted affinity 
higher than BBI-608 (Table 15). Like in the case of US, we take these values 
more into account as comparison between rather than a prediction. Otherwise 
they would be fairly strong binders which we believe is not the case. These values 
can be related directly to the method, MM-PBSA. Other techniques such as free 











Carprofen 17,9 ± 6,6 
Flurbiprofen 29,9 ± 6,5 
Ibuprofen 23,9 ± 4,8 
Naproxen 34,9 ± 5,4 
BBI-608 18,1 ± 2,6 
 
6.4 CAT analysis of STAT3 
As mentioned in previous sections STAT3 is a hard to target protein. A lack of 
structures co-crystallised with small molecule ligands hinders proof of its 
canonical binding site. Although there is evidence on its allosteric behaviour, most 
studies on the protein hotspot identification are inconclusive due to their lack of 
experimental validation. Therefore, in an attempt to identify potential binding 
sites, I performed cosolvent MD and its further analysis with CAT for STAT3.  
The same protocol as the CAT benchmark was followed. This includes selection 
of the same probes (acetamide, acetanilide, benzene, imidazole, isopropanol), at 
the same concentration, 10% (m/m), and that three times 50 ns replicas per 
cosolvent were performed for the CAT analysis. The STAT3 monomer, except 
the CC domain, was simulated instead of the dimer. 
Taking into account the data gathered in this work, it can be assumed that STAT3 
presented at least two binding regions: the pTyr site in the SH2 domain, and the 
DBD groove identified by Ji and coworkers133. CAT identified the pTyr site but 
struggled to properly map the buried DBD pocket (Figure 43). At the pTyr site 
several highly ranked clusters were mapped, mainly in the helix that comprises 
the pY+0 pocket including key residues K591 and R595 (Figure 43.b). Three 
different probes identified the aforementioned region: benzene, imidazole and 
isopropanol. Interestingly, other cosolvent clusters (mainly acetamide) were 
placed mainly in two other regions from the SH2 domain. These correspond to 
the preferential hotspots for AutoDock4 and UCSF DOCK6 mentioned in section 
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4.2.1.3 (Figure 43.c). Regarding the DBD site, no clusters identified the internal 
residues of the pocket, but all probes identified at different levels of preference 
the external face of the pocket (K573, T515 and D334) (Figure 43.d). Acetanilide 
seemed to have a different behaviour, as it does not map any region from the 
SH2 or Linker domain, meaning that it has a considerable preference for the 
DNA-Binding Domain. Its affinity is very favourable on the region close to R414, 
residue that as a gatekeeper for DNA exit as mentioned in 6.2.2 (Figure 43.e). 
 
Figure 43 STAT3 hotspots found by CAT. Clusters have the following colours assigned: 
acetamide as cyan, benzene as magenta, acetanilide as orange, imidazole as yellow, and 
isopropanol as green. A) Panoramic view of the STAT3 monomer and the respective top regions 
identified by CAT. B) The loop (K591-E594) that forms the pY+0 pocket from the pTyr site is 
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identified by different cosolvents with high ranks. C) The L site, identified previously with AutoDock 
molecular docking is also mapped by CAT clusters as well as the newly identified DBD pocket 
(D) and a pocket close to the gatekeeper R414 (E) 
Performing cosolvent MD and further CAT analysis with the STAT3 system is a 
challenge. STAT3 is a multidomain protein with scarce evidence around its 
“druggability”. Cosolvent MD has been mainly tested with small proteins and/or 
single domains. This means that the bigger the system, the larger number of 
probes to be found in the system leading to a potential clustering and/or phase 
separation. Nevertheless, these results were deemed as satisfactory. The main 
goal was to identify both the pTyr and DBD binding sites, and while we succeed 
with the first, CAT struggles to map the DBD pocket due to its “hidden” nature. 
Again, it is likely that the binding site would be mapped more accurately if longer 
simulations were performed, but the risk to undergo phase separation is too big. 
As mentioned in section 1.3 one way to overcome this issue could have been to 
use of repulsion potentials in combination with longer simulations. Furthermore, 
regions that were classified as the preferential SH2 domain binding site for 
AutoDock4 and UCSF DOCK6 are also mapped. I believe that these regions 
should be taken into higher account as for example OPB-31121127, one of the few 
inhibitors going through clinical trials, is believed to bind in the “AutoDock region”.  
It is also interesting how CAT maps an area close to R414, the gatekeeper 
residues for the DNA binding/unbinding process. If ligand binding were to be 
achieved in that region, it could lead to a new mechanism of inhibition. 




Protein Contacts Cosolvent CAT Rank 
STAT3 
pTyr site 
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Chapter 7 Conclusions 
The correct assessment of the structural changes within the protein target is 
crucial for the right evaluation of possible time-dependent binding sites. As such, 
an accurate tool is pivotal for selecting possible contact regions to be further 
studied.  While standard analysis of hotspot mapping quantifies primarily the 
volume of the binding region, cosolvent MD simulation followed by CAT analysis 
focuses on the cosolvent-induced conformational changes, to map, assess, and 
rank the putative ‘hotspots’, via an empirical scoring function. This characteristic 
gives the algorithm presented herein a high level of robustness and reliability in 
searching and ranking hotspots, as shown by the comparison with experimental 
data and FTMAP predictions. The scoring function implemented in CAT makes it 
unique and distinct from computational methodologies reported in the literature. 
In the present work, it has been developed, tested and validated the applicability 
of CAT analysis to detect several potentially druggable allosteric sites, which 
were detected by X-ray crystallography studies. The usage of five different 
cosolvent molecules demonstrated, at the same time, a broad sample space 
regarding interacting molecules and provides an insight on the chemical nature 
of the putative ligand moieties that would preferentially bind to the respective site. 
CAT is robust yet versatile: the analysis can be performed on cosolvent 
trajectories using any cosolvent molecule of choice.  
The major shortcoming of CAT observed so far was its inability to map some deep 
buried pockets. This could be attributed to insufficient sampling during MD 
simulation, however FTmap performs very well on this task. Although this issue 
may be easily sorted by longer MD simulation in water prior to cosolvent MD 
simulations, a combination of both tools could be an interesting approach. I 
understand that the principle in which FTMap is based is not the same, although 
they share some features. The main goal while choosing this tool as a 
comparison with CAT relied in the ease of use and fast results one could get. The 
use of cosolvent tools such as CAT can give more insights in the dynamics and 
crypticity of the target in comparison to FTMap. 
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In future works, I would aim to explore CAT analysis applied to multi-cosolvent 
trajectories and to address the sampling problem which underlies the sub-optimal 
performance in mapping the buried pockets. 
Using computational approaches based on atomistic molecular dynamics 
simulations, enabled me to understand the effects of specific STAT3 mutations, 
which were described in the literature, and to explain their modulation of the 
STAT3 activity. Consistently with Mertens and coworkers138, D570K mutation 
exerted its effect by enhancing interactions between STAT3 and DNA, which 
interfered with the DNA release by the STAT3 dimer and thus inhibited the 
protein’s function by not driving transcription and resisting dephosphorylation.  
Subsequently, recent identification of a plausible binding site for small molecule 
STAT3 inhibitor nababucasin (BBI-608) helped me to deconvolute its inhibition 
mechanism, with resembled the effect exerted by D570K mutation. The 
identification of the putative binding site for BBI-608 around the DNA binding 
domain may contribute to novel potent and selective STAT3 inhibitors, similarly 
as the binding site shown in Ji’s work133. The accuracy and similarity between the 
model and the available patent data, raising the question on why this pocket was 
not identified before. Mutated inter-domain residues E435, W546 and K551 unveil 
a poor binding to DNA, leading to another way of targeting STAT3 by disrupting 
theses residues, pointing towards possible novel allosteric binding sites. 
Structure-based ligand design targeting these novel pockets, coupled with novel 
methodologies, such as employing recently the developed FragLites237, is likely 
to expand a set of chemotypes active towards STAT3 and contribute to the 





A.1 Cosolvent MD simulation protocol 
Structure preparation  
The crystal structures used as starting conformations for the cosolvent MD 
simulations were in the apo state, whenever available (PDB codes are listed in 
Table 9). Structures were stripped of water molecules and any present cofactors 
and/or ligands. For structures with missing loops, the MODELLER238 interface in 
UCSF Chimera239 was used to rebuild the missing fragments. The best ZDOPE 
scored loops were selected to complete the model.  
Incomplete side chains were replaced using the Dunbrack rotamer library240, 
implemented in UCSF Chimera21. For side chains with multiple locations, the 
highest occupancy conformations have been selected.  Structural hydrogens 
were added and the following protein parametrisation was performed using the 
Gromacs 2016.03241 suite with AMBERFF99SB-ILDN148 force field. A cubic box 
was centred around the protein target with 1 nm distance between the protein 
extreme to the edge. A pre-defined number of molecular probes (cosolvent 
molecules) were randomly inserted into to the system, ensuring that after the 
following solvation with TIP3P waters there was a 10% (m/m) probe concentration 
in water in order to avoid phase separation and/or probe clustering. Each 
simulation used a single type of cosolvent molecule. The probe selection criteria 
consisted of using a series of drug-like small molecular fragments with a broad 
range of relevant properties, including hydrophilicity/hydrophobicity, aromaticity, 
and number of hydrogen-bonding acceptors/donors, with a diverse range of logP 
values. The following molecules were used: acetamide, benzene, acetanilide, 
imidazole and isopropanol. To diminish the effect of phase separation and 𝜋 − 𝜋 
stacking of aromatic and very hydrophobic cosolvent molecules such as 
benzene, an approach similar to Mackerell and colleagues242 was chosen, which 
relied on placing a dummy atom with a negligible negative charge (e=-0.01) in 
the centre of the 6-membered ring. All probes were parametrised using GAFF243 




MD simulation protocol 
To maintain the charge neutrality of the simulated unit, sodium and chloride ions 
were added to a concentration of 0.1 M. Bonds were constrained using the 
LINCS246 algorithm, with a 2 fs time step. The electrostatic interactions were 
calculated using the particle-mesh Ewald method, with a non-bonded cut-off set 
at 0.1 nm. All structures were minimised via the steepest descent algorithm for 
20000 steps was stopped when the maximum force fell below 1000kJ/mol/nm 
using the Verlet cutoff scheme.  After minimisation, heating via NVT ensemble 
was performed for 100 ps with a time step of 2 fs with position restraint (1000 
kJ/mol.mn2 in all three dimensions) applied to the backbone. The temperature 
coupling was set between the protein and the non-protein entities by using a 
Berendsen thermostat, with a time constant of 0.1 ps and the temperature set to 
reach 300 K with the pressure coupling off. Sequentially, a pressure NPT 
ensemble equilibration was performed followed by 100 ps, and three NPT 
ensemble production run replicas of 50 ns, totalling 150 ns for each different 
combination of protein and cosolvents, including the control simulations that are 
comprised of only protein-water systems. All production runs were unrestrained 
simulations.247 The temperature was set constant at 300 K by using a modified 
Berendsen thermostat (τ = 0.1 ps) 156. Pressure was kept constant at 1 bar by 
Parinello-Rahman isotropic coupling (τ = 2.0 ps) to a pressure bath.  
Data analysis has initially been done within the Gromacs package. For each data 
set, the analysis involved calculating root-mean-square deviation (RMSD), root-
mean-square fluctuations (RMSF), the covariance matrices and principal 
component analysis (PCA) and solvent accessible surface area (SASA) to 
analyse convergence of the runs. Afterwards, CAT analysis was employed for 
every dataset to identify any potentially druggable hotspots. 
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A.2 CAT supplementary information 
 
Figure A.1 PCA distribution of control simulations (protein-water) with cosolvent systems in 





Figure A.2 RMSD plots for HRAS 5 cosolvent runs and water simulation. 
 




Figure A.4 PCA distribution of control simulations (protein-water) with cosolvent systems in 
PTP1B. Black dots correspond to the control simulation, and orange dots to the cosolvent MD. 
 
 











Figure A.7 PCA distribution of control simulations (protein-water) with cosolvent systems in AR 






Figure A.8 RMSD plots for AR-LBD cosolvent runs and water simulation. 
 






Figure A.10 PCA distribution of control simulations (protein-water) with cosolvent systems for 
CDK2. Black dots correspond to the control simulation and orange dots to the cosolvent MD. 
 





Figure A.12 SASA plots for CDK2 5 cosolvent runs and water simulation. 
Table A.1 CAT scores for all targets and the top 10 clusters 
AR-LBD 
Rank Acetamide Benzene Isopropanol Acetanilide Imidazole 
1 -0,65 -0,68 -0,93 -1,15 -1,73 
2 -0,61 -0,64 -0,84 -0,98 -1,49 
3 -0,56 -0,54 -0,81 -0,83 -1,29 
4 -0,51 -0,45 -0,71 -0,74 -1,13 
5 -0,46 -0,35 -0,68 -0,62 -1,02 
6 -0,43 -0,35 -0,62 -0,54 -0,94 
7 -0,43 -0,33 -0,56 -0,54 -0,87 
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8 -0,41 -0,27 -0,5 -0,49 -0,84 
9 -0,41 -0,24 -0,42 -0,47 -0,82 
10 -0,4 -0,24 -0,42 -0,45 -0,81 
PTP1B 
Rank Acetamide Benzene Isopropanol Acetanilide Imidazole 
1 -2,3 -0,47 -1,65 -0,88 -1,68 
2 -1,08 -0,47 -0,92 -0,53 -1,02 
3 -0,8 -0,42 -0,58 -0,44 -0,78 
4 -0,68 -0,31 -0,57 -0,4 -0,77 
5 -0,67 -0,3 -0,49 -0,4 -0,74 
6 -0,54 -0,28 -0,43 -0,34 -0,73 
7 -0,53 -0,26 -0,42 -0,29 -0,65 
8 -0,52 -0,24 -0,42 -0,29 -0,62 
9 -0,51 -0,22 -0,41 -0,29 -0,58 
10 -0,51 -0,22 -0,4 -0,28 -0,57 
HRas 
Rank Acetamide Benzene Acetanilide Imidazole Isopropanol 
1 -0,64 -0,32 -0,4 -0,83 -0,55 
2 -0,64 -0,19 -0,33 -0,64 -0,5 
3 -0,57 -0,17 -0,3 -0,59 -0,49 
4 -0,52 -0,17 -0,28 -0,57 -0,49 
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5 -0,52 -0,16 -0,22 -0,56 -0,42 
6 -0,45 -0,15 -0,21 -0,51 -0,41 
7 -0,43 -0,15 -0,2 -0,49 -0,41 
8 -0,39 -0,14 -0,19 -0,45 -0,34 
9 -0,37 -0,14 -0,19 -0,44 -0,32 
10 -0,34 -0,08 -0,19 -0,41 -0,31 
CDK2 
Rank Acetamide Benzene Acetanilide Imidazole Isopropanol 
1 -0,74 -0,94 -0,89 -0,92 -1,21 
2 -0,67 -0,78 -0,87 -0,78 -1,01 
3 -0,61 -0,68 -0,71 -0,75 -0,74 
4 -0,57 -0,52 -0,63 -0,62 -62 
5 -0,56 -0,46 -0,59 -0,58 -0,62 
6 -0,55 -0,43 -0,57 -0,55 -0,53 
7 -0,5 -0,41 -0,56 -0,55 -0,47 
8 -0,5 -0,35 -0,54 -0,51 -0,46 
9 -0,48 -0,35 -0,53 -0,51 -0,45 







B.1 Chapter 6 Simulation/Docking protocol 
Molecular modelling of human STAT3 dimer.  
Initial models of dimeric human STAT3 (wild type and mutants) in complex with 
DNA were created using crystal structure of unphosphorylated mouse STAT3B 
(PDB code: 4E68), which spans residues 136-716. The N-terminal domain has 
been excluded from the structures subjected to the simulations. Loops spanning 
the residues 184-194 and 688-702 were modelled using MODELLER 
interface248,249 in UCSF Chimera250. The DNA double strand bounded to the 
model was designed based on 4E68, with the 5’-3’ strand sequence as 
TGCATTTCCCGTAATC. The final model was subjected to 20000 cycles of 
steepest descent energy minimisation. 
The STAT3 mutations (Figure 13), which were selected following the study by 
Mertens and coworkers138, were introduced in UCSF Chimera by swapping side 
chains to the target residues and adjusting new conformations using Dunbrack 
rotamer library integrated within UCSF Chimera. 
Modelling of ligand-bound STAT3. The crystal structure of ligand-bound 
STAT3 is yet not available, therefore we built the most similar model possible with 
the accessible data. Starting from the dimer model of wild-type STAT3 described 
in the previous section, molecular docking calculations were performed with 
MOE251, using napabucasin (BBI-608) as the ligand. To ensure the scoring 
function accuracy with the target and the best possible fit both blind (full dimer) 
and targeted docking (pocket described) were performed. 200 different 
conformations of the ligand were scored per each run using Triangle Matcher, 
and London dG for the first scoring function. Thereafter, the top 100 
conformations were rescored using Induced Fit and GBVI/WSA (Generalized-
Born volume integral/weighted surface area) score 251. From the final poses 
obtained, one for each monomer was selected based on score, interactions and 
consistency with the experimental structure shown in Ji’s work133 which shows 




Molecular dynamics and umbrella sampling simulations. In order to study the 
dynamics effects of mutations in the STAT3 dimer, each of the listed mutation 
were created in UCSF Chimera250. Structural hydrogens were added and the 
following protein parametrisation was performed using the Gromacs 2016.03252 
suite with AMBERFF99SB-ILDN253 force field. Before pulling the DNA from the 
complex, the systems were relaxed with a short equilibrium MD production run. 
Hence, a 1 nm cubic box was centred on the structure and the system is solvated 
with TIP3P waters.  Sodium and chloride ions were added to a concentration of 
0.1 M resulting in systems with more than seven hundred thousand atoms. Bonds 
were constrained using the LINCS254 algorithm. The electrostatic interactions 
were calculated using particle-mesh Ewald method, with a non-bonded cut-off set 
at 0.1 nm. All structures were minimised via the steepest descent algorithm for 
20,000 steps of 0.02 nm, and minimisations were stopped when the maximum 
force fell below 1000kJ/mol/nm using the Verlet cut-off scheme255. After 
minimisation, temperature equilibration  was performed for 100ps with a time step 
of 2fs with position restraints applied to the backbone using an NVT. The 
temperature coupling was set between the protein and the non-protein entities by 
using a Berendsen thermostat256, with a time constant of 0.1 ps, and the 
temperature set to reach 300K with the pressure coupling off. Sequentially, a 
pressure NPT equilibration was performed followed by 100ps of an NVT 
equilibration, the following 100ps of NPT equilibration, and a production run of 
100 ns. Temperature was set constant at 300K by using a modified Berendsen 
thermostat (τ = 0.1 ps)256. Pressure was kept constant at 1 bar by Parinello-
Rahman isotropic coupling (τ = 2.0 ps) to a pressure bath257.  
For the umbrella sampling simulation, a 50 ns pre-umbrella equilibration was 
made, with the complex rotate its principal axis to align with the z-axis of the 
simulation box. A pull sampling was used using a constant force approach (k = 
1000 kJ/mol/nm, with a rate of 0.01 nm) between the centres of masses of SH2 
domain and the DNA double helix, along the described path shown in Figure 2. 
From each corresponding pull simulation, a series of conformations have been 
selected in order to sample the process of entering-exiting the DNA-binding site. 
Each of the 25 selected umbrella windows has been through a 1ns NPT 
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equilibration run, followed by a 5ns NPT distance restrained production run, 
totalizing per system, 135ns of simulation time, using the previously described 
protocol and parameters. Afterwards, the potential of mean force (PMF) curve of 
the studied scenario has been calculated with the Weighted Histogram Analysis 
Method (WHAM) tool from Gromacs258, and associated errors was calculated 
using both a convergence criteria and the implemented bootstrap method in 
gromacs WHAM. All calculations for the analysis were made using the gromacs 
tools. 
 
B.2 STAT3 supplementary information 
 
Figure A.13 RMSD values for the three performed simulations of STAT3-BBI608 complexes. For 
all three replicas, the systems attained convergence. However, the replica C had shown some 




Figure A.14 PMF per ns for the WT apo STAT3, where ξ is the DNA pulling coordinate. We can 
see a clear convergence after 5 ns. The variations are negligible after 7 ns. 
 
Figure A.15 PMF per ns for the K551A STAT3 mutant, where ξ is the DNA pulling coordinate. 
After 7 ns, the overall energy of unbinding has converged. However, after 9 ns, a new energetic 




Figure A.16 PMF per ns for the EE434435AA STAT3 double mutant, where ξ is the DNA pulling 
coordinate. The system has a steady convergence after 5 ns, with negligible fluctuations after 7 
ns. 
 
Figure A.17 PMF per ns for the W546A STAT3 mutant, where ξ is the DNA pulling coordinate. 





Figure A.18 6 PMF per ns for the D570K STAT3 mutant, where ξ is the DNA pulling coordinate. 
The system has a steady convergence after 3 ns, with negligible fluctuations after 5 ns. 
 
Figure A.19 PMF per ns for the BBI608-STAT3-DNA complex. where ξ is the DNA pulling 
coordinate. The system has a steady convergence after 5 ns. Regardless of the PMF landscape 





Figure A.20 8 RMSD values for the performed STAT3-BBI608 simulations without DNA. Given 
the lack of DNA structure to stabilize the dimer, the RMSD fluctuates significantly more in 






Computational methods and procedures described in this work were 
accomplished with in-house systems and high performance computing resources 
(HPC): 
C.1.1 In-house equipment 
Local machine: 
• 1 Intel Core E3-1200 processor (4.00 GHz, 8 cores, X MB cache) 
• 1 GeForce GTX 1070 GPU 
• 16 GB memory 
• 6 TB SATA Disk 
C.1.2 HPC resources 
Rocket (Newcastle University) 
110 standard nodes, each with: 
• 2 Intel Xeon E5-2699 v4 processors (2.2 GHz, 22 cores, 55 MB cache) 
• 44 cores (2 processors * 22 cores), totalling 4840 across the standard 
nodes 
• 128 GB memory - (8 DDR4 RDIMMs, each with 16GB) – ie. 2.9 GB per 
core 
• 600 GB SAS disk (469 GB scratch space) 
6 medium (M) nodes: 
• 2 Intel Xeon E5-2699 v4 processors (2.2 GHz, 22 cores, 55 MB cache) 
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• 44 cores (2 processors * 22 cores), totalling 264 across the medium nodes 
• 512 GB memory - (16 DDR4 RDIMMs, each with 32GB) – ie. 11.6 GB per 
core 
• 1200 GB SAS disk (1.1 TB scratch space)  
4 large (L) nodes: 
• 2 Intel Xeon E5-2699 v4 processors (2.2 GHz, 22 cores, 55 MB cache) 
• 44 cores (2 processors * 22 cores), totalling 176 across the large nodes 
• 512 GB memory - (16 DDR4 RDIMMs, each with 32GB) – ie. 11.6 GB per 
core 
• 2 * 4000 GB SAS disks (7.2 TB scratch space) 
2 extra-large (XL) nodes: 
• 4 Intel Xeon E7-4830 v4 processors (2.0 GHz, 14 cores, 35 MB cache) 
• 56 cores (4 processors * 14 cores), totalling 112 across the extra-large 
nodes 
• 1536 GB memory - (48 DDR4 RDIMMs, each with 32GB) – ie. 27.4 GB 
per core 
• 8 * 1200 GB SAS disks (8.7 TB scratch space) 
1 GPU node: 
• 2 * 16 core IBM POWER9 processors (2.6GHz, 3.09 GHz Turbo) 
• 4 NVIDIA Tesla V100 GPUs, each with 16GB VRAM and NVLink2 
interconnect  
• 256 GB memory 
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• 893 GB scratch space 
 
C.2 Software used 
Name Version Reference 
Data visualization and analysis 
VMD 1.9.3 202 
Pymol 2.0 259 
UCSF Chimera 1.12 239 
RStudio 1.2.5001 260 
Docking 
MOE 2016.01 190 
AutoDock 4.2.6 182 
AutoDock Tools 1.5.6 182 
Raccoon 1.0b 261 
UCSF DOCK 6.9 181 
Molecular dynamics simulation and analysis 






D.1 Digital repositories 
Digital data such as molecular docking results, modelled systems or molecular 
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